Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
35 "Prostate"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Determinants of Prostate Cancer Screening in Korean Men: A Nationwide Study Using the Korean National Cancer Screening Survey 2023
Giap Viet Nguyen, Kyeongmin Lee, Hyeon Ji Lee, EunKyo Kang, Mina Suh, Jae Kwan Jun, Kui Son Choi
Received September 8, 2024  Accepted October 28, 2024  Published online October 29, 2024  
DOI: https://doi.org/10.4143/crt.2024.879    [Accepted]
AbstractAbstract PDF
Purpose
Research on the prevalence of prostate cancer (PCa) screening and reasons for undergoing screening is limited. We aimed to identify the factors influencing PCa screening behavior and explore the underlying motivations among Korean men.
Materials and Methods
This cross-sectional study used data from the 2023 Korean National Cancer Screening Survey, which employs a nationally representative random sampling method. This study included 1,784 men aged 40-74 years. The respondents reported their experiences with PCa screening. Multivariable logistic regression analysis was conducted to identify the factors associated with participation in PCa screening.
Results
The lifetime PCa screening rate was 18.6%. Among screening modalities, transrectal ultrasonography was the most frequently used (31.9%), followed by prostate-specific antigen tests (25.6%) and digital rectal examinations (21.5%). The multivariable analysis identified several factors that significantly increased the likelihood of screening participation, including older age, living with a spouse, poor self-reported health, and abstinence from alcohol consumption in the previous 12 months. Men who had undergone colorectal cancer screening were more likely to participate in PCa screening (adjusted odds ratio, 4.01; 95% confidence interval, 2.03–7.93) than those who had not. The primary motivations for screening were recommendations from family or social networks (31.9%) and inclusion in health examination packages (24.3%), whereas healthcare provider recommendations (18%) and symptomatic concerns (5.7%) were the least influential.
Conclusion
Our findings highlight the importance of providing evidence-based information for PCa screening recommendations and the need for improved communication and implementation of a shared decision-making approach for PCa screening in Korea.
  • 318 View
  • 25 Download
Close layer
Genitourinary cancer
Bilateral Seminal Vesicle Invasion as a Strong Prognostic Indicator in T3b Prostate Cancer Patients Following Radical Prostatectomy: A Comprehensive, Multicenter, Long-term Follow-up Study
Jungyo Suh, In Gab Jeong, Hwang Gyun Jeon, Chang Wook Jeong, Sangchul Lee, Seong Soo Jeon, Seok-Soo Byun, Cheol Kwak, Hanjong Ahn
Cancer Res Treat. 2024;56(3):885-892.   Published online January 5, 2024
DOI: https://doi.org/10.4143/crt.2023.1264
AbstractAbstract PDFPubReaderePub
Purpose
Pathologic T3b (pT3b) prostate cancer, characterized by seminal vesicle invasion (SVI), exhibits variable oncological outcomes post–radical prostatectomy (RP). Identifying prognostic factors is crucial for patient-specific management. This study investigates the impact of bilateral SVI on prognosis in pT3b prostate cancer.
Materials and Methods
We evaluated the medical records of a multi-institutional cohort of men who underwent RP for prostate cancer with SVI between 2000 and 2012. Univariate and multivariable analyses were performed using Kaplan-Meier analysis and covariate-adjusted Cox proportional hazard regression for biochemical recurrence (BCR), clinical progression (CP), and cancer-specific survival (CSS).
Results
Among 770 men who underwent RP without neo-adjuvant treatment, median follow-up was 85.7 months. Patients with bilateral SVI had higher preoperative prostate-specific antigen levels and clinical T category (all p < 0.001). Extracapsular extension, tumor volume, lymph node metastasis (p < 0.001), pathologic Gleason grade group (p < 0.001), and resection margin positivity (p < 0.001) were also higher in patients with bilateral SVI. The 5-, 10-, and 15-year BCR-free survival rates were 23.9%, 11.7%, and 8.5%; CP-free survival rates were 82.8%, 62.5%, and 33.4%; and CSS rates were 96.4%, 88.1%, and 69.5%, respectively. The bilateral SVI group demonstrated significantly lower BCR-free survival rates, CP-free survival rates, and CSS rates (all p < 0.001). Bilateral SVI was independently associated with BCR (hazard ratio, 1.197; 95% confidence interval, p=0.049), CP (p=0.022), and CSS (p=0.038) in covariate-adjusted Cox regression.
Conclusion
Bilateral SVI is a robust, independent prognostic factor for poor oncological outcomes in pT3b prostate cancer.

Citations

Citations to this article as recorded by  
  • Role of [18F]-PSMA-1007 PET radiomics for seminal vesicle invasion prediction in primary prostate cancer
    Liang Luo, Xinyi Wang, Hongjun Xie, Hua Liang, Jungang Gao, Yang Li, Yuwei Xia, Mengmeng Zhao, Feng Shi, Cong Shen, Xiaoyi Duan
    Computers in Biology and Medicine.2024; 183: 109249.     CrossRef
  • 3,950 View
  • 125 Download
  • 1 Crossref
Close layer
A Nationwide Study of Differences in Surgical Treatment Rates and Oncological Outcomes for Prostate Cancer according to Economic Status and Region
Sangjun Yoo, Sohee Oh, Min Chul Cho, Hwancheol Son, Hyeon Jeong
Cancer Res Treat. 2023;55(2):652-658.   Published online December 12, 2022
DOI: https://doi.org/10.4143/crt.2022.893
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We investigated the effects of economic status (classified based on insurance type and residential area) on oncological outcomes of prostate cancer using a nationwide database. We additionally investigated oncological outcomes based on economic status and residential area in patients who underwent surgical treatment.
Materials and Methods
The study included 75,518 men with newly diagnosed prostate cancer between 2009 and 2018 in whom oncological outcomes were investigated based on economic status and residential area. Among the 75,518 men with prostate cancer, the data of 29,973 men who underwent radical prostatectomy were further analyzed. Multivariate analysis was performed to determine the effects of economic status and residential area on postoperative oncological outcomes.
Results
Among the 75,518 patients with prostate cancer, 3,254 (4.31%) were medical aid beneficiaries. The 5-year overall survival rates were 81.2% and 64.8% in the health insurance and medical aid groups, respectively. Radical prostatectomy was more common in the health insurance group, and surgical intervention was significantly affected by the residential area. Among patients who underwent surgery, 5-year androgen deprivation therapy–free and overall survival were better in the health insurance group. Multivariate analysis showed that insurance type and residential area were significantly associated with the androgen deprivation therapy–free and overall survival after adjustment for other variables.
Conclusion
Economic status and residential area were shown to affect not only treatment patterns but also post-diagnosis and postoperative oncological outcomes. Political support for early diagnosis and appropriate treatment of prostate cancer is warranted for medically vulnerable populations.
  • 4,225 View
  • 126 Download
Close layer
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
Cancer Res Treat. 2022;54(4):1191-1199.   Published online December 7, 2021
DOI: https://doi.org/10.4143/crt.2021.985
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer.
Materials and Methods
Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters.
Results
When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%.
Conclusion
A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.

Citations

Citations to this article as recorded by  
  • New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): AJR Expert Panel Narrative Review
    Adriano B. Dias, Silvia D. Chang, Fiona M. Fennessy, Soleen Ghafoor, Sangeet Ghai, Valeria Panebianco, Andrei S. Purysko, Francesco Giganti
    American Journal of Roentgenology.2025; : 1.     CrossRef
  • A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer
    Laura Evangelista, Fabio Zattoni, Marta Burei, Daniele Bertin, Eugenio Borsatti, Tanja Baresic, Mohsen Farsad, Emanuela Trenti, Mirco Bartolomei, Stefano Panareo, Luca Urso, Giuseppe Trifirò, Elisabetta Brugola, Franca Chierichetti, Davide Donner, Lucia S
    Journal of Nuclear Medicine.2024; 65(7): 1013.     CrossRef
  • Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer
    Inki Lee, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Jae Hun Ahn, Yong Jin Lee, Gi Jeong Cheon, Dae Yoon Chi, Sang Moo Lim
    Diagnostics.2023; 13(16): 2649.     CrossRef
  • 6,508 View
  • 179 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
Prediction of Pathologic Findings with MRI-Based Clinical Staging Using the Bayesian Network Modeling in Prostate Cancer: A Radiation Oncologist Perspective
Chan Woo Wee, Bum-Sup Jang, Jin Ho Kim, Chang Wook Jeong, Cheol Kwak, Hyun Hoe Kim, Ja Hyeon Ku, Seung Hyup Kim, Jeong Yeon Cho, Sang Youn Kim
Cancer Res Treat. 2022;54(1):234-244.   Published online May 17, 2021
DOI: https://doi.org/10.4143/crt.2020.1221
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop a model for predicting pathologic extracapsular extension (ECE) and seminal vesicle invasion (SVI) while integrating magnetic resonance imaging-based T-staging (cTMRI, cT1c-cT3b).
Materials and Methods
A total of 1,915 who underwent radical prostatectomy between 2006-2016 met the inclusion/exclusion criteria. We performed a multivariate logistic regression analysis as well as Bayesian network (BN) modeling based on possible confounding factors. The BN model was internally validated using 5-fold validation.
Results
According to the multivariate logistic regression analysis, initial prostate-specific antigen (iPSA) (β=0.050, p < 0.001), percentage of positive biopsy cores (PPC) (β=0.033, p < 0.001), both lobe involvement on biopsy (β=0.359, p=0.009), Gleason score (β=0.358, p < 0.001), and cTMRI (β=0.259, p < 0.001) were significant factors for ECE. For SVI, iPSA (β=0.037, p < 0.001), PPC (β=0.024, p < 0.001), Gleason score (β=0.753, p < 0.001), and cTMRI (β=0.507, p < 0.001) showed statistical significance. BN models to predict ECE and SVI were also successfully established. The overall area under the receiver operating characteristic curve (AUC)/accuracy of the BN models were 0.76/73.0% and 0.88/89.6% for ECE and SVI, respectively. According to internal comparison between the BN model and Roach formula, BN model had improved AUC values for predicting ECE (0.76 vs. 0.74, p=0.060) and SVI (0.88 vs. 0.84, p < 0.001).
Conclusion
Two models to predict pathologic ECE and SVI integrating cTMRI were established and installed on a separate website for public access to guide radiation oncologists.

Citations

Citations to this article as recorded by  
  • Measurements of target volumes and organs at risk using DW‑MRI in patients with central lung cancer accompanied with atelectasis
    Xinli Zhang, Tong Liu, Hong Zhang, Mingbin Zhang
    Molecular and Clinical Oncology.2023;[Epub]     CrossRef
  • 6,357 View
  • 145 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Genitourinary Cancer
A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population
Tae Il Noh, Chang Wan Hyun, Ha Eun Kang, Hyun Jung Jin, Jong Hyun Tae, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
Cancer Res Treat. 2021;53(4):1148-1155.   Published online December 31, 2020
DOI: https://doi.org/10.4143/crt.2020.1068
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop and validate a predictive model for the assessment of clinically significant prostate cancer (csPCa) in men, prior to prostate biopsies, based on bi-parametric magnetic resonance imaging (bpMRI) and clinical parameters.
Materials and Methods
We retrospectively analyzed 300 men with clinical suspicion of prostate cancer (prostate-specific antigen [PSA] ≥ 4.0 ng/mL and/or abnormal findings in a digital rectal examination), who underwent bpMRI-ultrasound fusion transperineal targeted and systematic biopsies in the same session, at a Korean university hospital. Predictive models, based on Prostate Imaging Reporting and Data Systems scores of bpMRI and clinical parameters, were developed to detect csPCa (intermediate/high grade [Gleason score ≥ 3+4]) and compared by analyzing the areas under the curves and decision curves.
Results
A predictive model defined by the combination of bpMRI and clinical parameters (age, PSA density) showed high discriminatory power (area under the curve, 0.861) and resulted in a significant net benefit on decision curve analysis. Applying a probability threshold of 7.5%, 21.6% of men could avoid unnecessary prostate biopsy, while only 1.0% of significant prostate cancers were missed.
Conclusion
This predictive model provided a reliable and measurable means of risk stratification of csPCa, with high discriminatory power and great net benefit. It could be a useful tool for clinical decision-making prior to prostate biopsies.

Citations

Citations to this article as recorded by  
  • Abbreviated MRI Protocols in the Abdomen and Pelvis
    Kristina I. Ringe, Jin Wang, Ying Deng, Shan Pi, Amine Geahchan, Bachir Taouli, Mustafa R. Bashir
    Journal of Magnetic Resonance Imaging.2024; 59(1): 58.     CrossRef
  • Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer
    Arya Haj-Mirzaian, Kristine S. Burk, Ronilda Lacson, Daniel I. Glazer, Sanjay Saini, Adam S. Kibel, Ramin Khorasani
    JAMA Network Open.2024; 7(3): e244258.     CrossRef
  • The Barcelona Predictive Model of Clinically Significant Prostate Cancer
    Juan Morote, Angel Borque-Fernando, Marina Triquell, Anna Celma, Lucas Regis, Manel Escobar, Richard Mast, Inés M. de Torres, María E. Semidey, José M. Abascal, Carles Sola, Pol Servian, Daniel Salvador, Anna Santamaría, Jacques Planas, Luis M. Esteban, E
    Cancers.2022; 14(6): 1589.     CrossRef
  • Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
    Sexual Medicine.2022; 10(3): 1.     CrossRef
  • Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
    Juan Morote, Angel Borque-Fernando, Marina Triquell, Anna Celma, Lucas Regis, Richard Mast, Inés M. de Torres, María E. Semidey, José M. Abascal, Pol Servian, Anna Santamaría, Jacques Planas, Luis M. Esteban, Enrique Trilla
    Cancers.2022; 14(10): 2374.     CrossRef
  • Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
    Marina Triquell, Miriam Campistol, Ana Celma, Lucas Regis, Mercè Cuadras, Jacques Planas, Enrique Trilla, Juan Morote
    Cancers.2022; 14(19): 4747.     CrossRef
  • 6,683 View
  • 165 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
Cancer Res Treat. 2020;52(1):301-308.   Published online August 1, 2019
DOI: https://doi.org/10.4143/crt.2019.194
AbstractAbstract PDFPubReaderePub
Purpose
Prostate cancer (PCa) incidence is affected by aging phenomenon and performance of screening test. In United States, PCa incidence is affected by period effect of U.S. Preventive Services Task Force (USPSTF) recommendation. However, no study has reported the effect of USPSTF recommendation or aging phenomenon on PCa incidence in South Korea. Thus, the objective of this study was to investigate effects of age, period, and birth cohort on PCa incidence using age-period-cohort analysis.
Materials and Methods
Annual report of cancer statistics between 2003 and 2013 from National Health Insurance Service (NHIS) in South Korea for the number of PCa patients and Korean Statistical Information Service (KOSIS) data between 2003 and 2013 from national statistics in South Korea for the number of Korean male population were used. Age-period-cohort models were used to investigate effects of age, period, and birth cohort on PCa incidence.
Results
Overall PCa incidence in South Korea was increased 8.8% in annual percentage (95% confidential interval, 6.5 to 11.2; p < 0.001). It showed an increasing pattern from 2003 to 2011 but a decreasing pattern from 2011 to 2013. Age increased the risk of PCa incidence. However, the speed of increase was slower with increasing age. PCa incidence was increased 1.4 times in 2008 compared to that in 2003 or 2013. Regarding cohort effect, the risk of PCa incidence started to increase from 1958 cohort.
Conclusion
PCa incidence was affected by period of specific year. There was a positive cohort effect on PCa incidence associated with age structural change.

Citations

Citations to this article as recorded by  
  • Association Between Prostate Cancer Detection Rate and Year of Prostate Biopsy
    Young Jun Uhm, Woojin Bang, Jae Hoon Chung, Cheol Young Oh, Hwanik Kim, Jin Seon Cho
    Life.2025; 15(2): 260.     CrossRef
  • Incidence trends and spatial distribution of thyroid cancer in the Chinese female population from 1990 to 2019
    Xiaowei Qiao, Yunshang Cui, Changgeng Ma, Chunxiao Ma, Bingyu Bai, Chunping Wang
    Asia-Pacific Journal of Oncology Nursing.2024; 11(7): 100529.     CrossRef
  • Exploring Prostate Cancer Incidence Trends and Age Change in Cancer Registration Areas of Jiangsu Province, China, 2009 to 2019
    Hairong Zhou, Xin Hong, Weigang Miao, Weiwei Wang, Chenchen Wang, Renqiang Han, Jinyi Zhou
    Current Oncology.2024; 31(9): 5516.     CrossRef
  • A Web-Based Decision Aid for Informed Prostate Cancer Screening: Development and Pilot Evaluation
    Wonyoung Jung, In Young Cho, Keun Hye Jeon, Yohwan Yeo, Jae Kwan Jun, Mina Suh, Ansuk Jeong, Jungkwon Lee, Dong Wook Shin
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Regional disparities in major cancer incidence in Korea, 1999-2018
    Eun Hye Park, Mee Joo Kang, Kyu-Won Jung, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Hyun-Joo Kong, Chang Kyun Choi, Jeong-Soo Im, Hong Gwan Seo
    Epidemiology and Health.2023; 45: e2023089.     CrossRef
  • Time Trends in Psoriasis and Psoriatic Arthritis Incidence from 2002 to 2016 in Taiwan: An Age–Period–Cohort Analysis
    Yu-Tsung Chen, Chih-Yi Wu, Yu-Ling Li, Li-Ying Chen, Hung-Yi Chiou
    Journal of Clinical Medicine.2022; 11(13): 3744.     CrossRef
  • The burden of endometriosis in China from 1990 to 2019
    Yan Wang, Xiaoyan Wang, Kaijun Liao, Baoqin Luo, Jiashou Luo
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients
    Sung Han Kim, Whi-An Kwon, Jae Young Joung
    The World Journal of Men's Health.2021; 39(2): 358.     CrossRef
  • Can Prostate-Specific Antigen Density Be an Index to Distinguish Patients Who Can Omit Repeat Prostate Biopsy in Patients with Negative Magnetic Resonance Imaging?
    Jiwoong Yu, Youngjun Boo, Minyong Kang, Hyun Hwan Sung, Byong Chang Jeong, Seongil Seo, Seong soo Jeon, Hyunmoo Lee, Hwang Gyun Jeon
    Cancer Management and Research.2021; Volume 13: 5467.     CrossRef
  • Long-term trends in the incidence of endometriosis in China from 1990 to 2019: a joinpoint and age–period–cohort analysis
    Jinhui Feng, Shitong Zhang, Jiadong Chen, Jie Yang, Jue Zhu
    Gynecological Endocrinology.2021; 37(11): 1041.     CrossRef
  • Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data
    Yohwan Yeo, Dong Wook Shin, Jungkwon Lee, Kyungdo Han, Sang Hyun Park, Keun Hye Jeon, Jungeun Shin, Aesun Shin, Jinsung Park
    Journal of Personalized Medicine.2021; 12(1): 2.     CrossRef
  • Association between SOD2 V16A variant and urological cancer risk
    Li-Feng Zhang, Kai Xu, Bo-Wen Tang, Wei Zhang, Wei Yuan, Chuang Yue, Li Shi, Yuan-Yuan Mi, Li Zuo, Li-Jie Zhu
    Aging.2020; 12(1): 825.     CrossRef
  • 7,202 View
  • 247 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population
Sung Uk Lee, Kwan Ho Cho, Won Park, Won Kyung Cho, Jae-Sung Kim, Chan Woo Wee, Young Seok Kim, Jin Ho Kim, Taek-Keun Nam, Jaeho Cho, Song Mi Jeong, Youngkyong Kim, Su Jung Shim, Youngmin Choi, Jun-Sang Kim
Cancer Res Treat. 2020;52(1):167-180.   Published online June 25, 2019
DOI: https://doi.org/10.4143/crt.2019.126
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the clinical outcomes of postoperative radiotherapy (PORT) patients who underwent radical prostatectomy for localized prostate cancer.
Materials and Methods
Localized prostate cancer patients who received PORT after radical prostatectomy between 2001 and 2012 were identified retrospectively in a multi-institutional database. In total, 1,117 patients in 19 institutions were included. Biochemical failure after PORT was defined as prostate-specific antigen (PSA) ≥ nadir+2 after PORT or initiation of androgen deprivation therapy (ADT) for increasing PSA regardless of its value.
Results
Ten-year biochemical failure-free survival, clinical failure-free survival, distant metastasisfree survival, overall survival (OS), and cause-specific survival were 60.5%, 76.2%, 84.4%, 91.1%, and 96.6%, respectively, at a median of 84 months after PORT. Pre-PORT PSA ≤ 0.5 ng/ml and Gleason’s score ≤ 7 predicted favorable clinical outcomes, with 10-year OS rates of 92.5% and 94.1%, respectively. The 10-year OS rate was 82.7% for patients with a PSA > 1.0 ng/mL and 86.0% for patients with a Gleason score of 8-10. The addition of longterm ADT (≥ 12 months) to PORT improved OS, particularly in those with a Gleason score of 8-10 or ≥ T3b.
Conclusion
Clinical outcomes of PORT in a Korean prostate cancer population were very similar to those in Western countries. Lower Gleason score and serum PSA level at the time of PORT were significantly associated with favorable outcomes. Addition of long-term ADT (≥ 12 months) to PORT should be considered, particularly in unfavorable risk patients with Gleason scores of 8-10 or ≥ T3b.

Citations

Citations to this article as recorded by  
  • Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
    Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
    Cancer Research and Treatment.2022; 54(4): 1191.     CrossRef
  • A discussion on controversies and ethical dilemmas in prostate cancer screening
    Satish Chandra Mishra
    Journal of Medical Ethics.2021; 47(3): 152.     CrossRef
  • Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
    Sung Uk Lee, Kwan Ho Cho, Jin Ho Kim, Young Seok Kim, Taek-Keun Nam, Jae-Sung Kim, Jaeho Cho, Seo Hee Choi, Su Jung Shim, Jin Hee Kim, Ah Ram Chang
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • 7,963 View
  • 209 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Inherited NBN Mutations and Prostate Cancer Risk and Survival
Bogna Rusak, Wojciech Kluźniak, Dominika Wokołorczykv, Klaudia Stempa, Aniruddh Kashyap, Jacek Gronwald, Tomasz Huzarski, Tadeusz Dębniak, Anna Jakubowska, Bartłomiej Masojć, Mohammad R. Akbari, Steven A. Narodv, Jan Lubiński, Cezary Cybulski, The Polish Hereditary Prostate Cancer Consortium
Cancer Res Treat. 2019;51(3):1180-1187.   Published online December 13, 2018
DOI: https://doi.org/10.4143/crt.2018.532
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
To establish the contribution of four founder alleles of NBN to prostate cancer risk and cancer survival.
Materials and Methods
Five thousand one hundred eighty-nine men with prostate cancer and 6,152 controls were genotyped for four recurrent variants of NBN (657del5, R215W, I171V, and E185Q).
Results
The NBN 657del5 mutation was detected in 74 of 5,189 unselected cases and in 35 of 6,152 controls (odds ratio [OR], 2.5; p < 0.001). In carriers of 657del5 deletion, the cancer risk was restricted to men with the GG genotype of the E185Q variant of the same gene. Among men with the GG genotype, the OR associated with 657del5 was 4.4 (95% confidence interval [CI], 2.4 to 8.0). Among men with other E185Q genotypes, the OR associated with 657del5 was 1.4 (95% CI, 0.8 to 2.4) and the interaction was significant (homogeneity p=0.006). After a median follow-up of 109 months, mortality was worse for 657del5 mutation carriers than for non-carriers (hazard ratio [HR], 1.6; p=0.001). The adverse effect of 657del5 on survival was only seen on the background of the GG genotype of E185Q (HR, 1.9; p=0.0004).
Conclusion
The NBN 657del5 mutation predisposes to poor prognosis prostate cancer. The pathogenicity of this mutation, with regards to both prostate cancer risk and survival, is modified by a missense variant of the same gene (E185Q).

Citations

Citations to this article as recorded by  
  • Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival
    Edward J. Saunders, Tokhir Dadaev, Mark N. Brook, Sarah Wakerell, Koveela Govindasami, Reshma Rageevakumar, Nafisa Hussain, Andrea Osborne, Diana Keating, Artitaya Lophatananon, Kenneth R. Muir, Burcu F. Darst, David V. Conti, Christopher A. Haiman, Anton
    European Urology Oncology.2024; 7(2): 248.     CrossRef
  • Germline pathogenic variants in the MRE11, RAD50, and NBN (MRN) genes in cancer predisposition: A systematic review and meta‐analysis
    Barbora Stastna, Tatana Dolezalova, Katerina Matejkova, Barbora Nemcova, Petra Zemankova, Marketa Janatova, Petra Kleiblova, Jana Soukupova, Zdenek Kleibl
    International Journal of Cancer.2024; 155(9): 1604.     CrossRef
  • Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer
    Burcu F. Darst, Ed Saunders, Tokhir Dadaev, Xin Sheng, Peggy Wan, Loreall Pooler, Lucy Y. Xia, Stephen Chanock, Sonja I. Berndt, Ying Wang, Alpa V. Patel, Demetrius Albanes, Stephanie J. Weinstein, Vincent Gnanapragasam, Chad Huff, Fergus J. Couch, Alicja
    JAMA Oncology.2023; 9(11): 1514.     CrossRef
  • Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications
    Hamidreza Saeidi, Ikmal Hisyam Bakrin, Chandramathi Samudi Raju, Patimah Ismail, Mohsen Saraf, Mohd Ghani Khairul-Asri
    Advances in Medical Sciences.2023; 68(2): 359.     CrossRef
  • Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity
    Gulnur Zhunussova, Nazgul Omarbayeva, Dilyara Kaidarova, Saltanat Abdikerim, Natalya Mit, Ilya Kisselev, Kanagat Yergali, Aigul Zhunussova, Tatyana Goncharova, Aliya Abdrakhmanova, Leyla Djansugurova
    Oncotarget.2023; 14(1): 860.     CrossRef
  • Genetic predisposition to prostate cancer: an update
    Holly Ni Raghallaigh, Rosalind Eeles
    Familial Cancer.2022; 21(1): 101.     CrossRef
  • Association of germline rare pathogenic mutations in guideline‐recommended genes with prostate cancer progression: A meta‐analysis
    Zhuqing Shi, Lucy Lu, William Kyle Resurreccion, Wancai Yang, Jun Wei, Qiang Wang, Valentina Engelmann, Siqun Lilly Zheng, Kathleen A. Cooney, William B. Isaacs, Brian T. Helfand, Jim Lu, Jianfeng Xu
    The Prostate.2022; 82(1): 107.     CrossRef
  • Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men
    Marta Heise, Piotr Jarzemski, Dagmara Nowak, Aneta Bąk, Anna Junkiert-Czarnecka, Maria Pilarska-Deltow, Maciej Borysiak, Beata Pilarska, Olga Haus
    Cancer Control.2022;[Epub]     CrossRef
  • Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients
    Dong Zhang, Xinchi Xu, Yuang Wei, Xinglin Chen, Guangyao Li, Zhongwen Lu, Xu Zhang, Xiaohan Ren, Shangqian Wang, Chao Qin
    Cancer Control.2022;[Epub]     CrossRef
  • Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS
    Ingrid P. Vogelaar, Stephanie Greer, Fan Wang, GiWon Shin, Billy Lau, Yajing Hu, Sigurdis Haraldsdottir, Rocio Alvarez, Dennis Hazelett, Peter Nguyen, Francesca P. Aguirre, Maha Guindi, Andrew Hendifar, Jessica Balcom, Anna Leininger, Beth Fairbank, Hanle
    Cancers.2022; 15(1): 228.     CrossRef
  • Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study
    Questa Karlsson, Mark N. Brook, Tokhir Dadaev, Sarah Wakerell, Edward J. Saunders, Kenneth Muir, David E. Neal, Graham G. Giles, Robert J. MacInnis, Stephen N. Thibodeau, Shannon K. McDonnell, Lisa Cannon-Albright, Manuel R. Teixeira, Paula Paulo, Marta C
    European Urology Oncology.2021; 4(4): 570.     CrossRef
  • Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes
    Tiffany Davia Ricketts, Nestor Prieto-Dominguez, Pramod Sreerama Gowda, Eric Ubil
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Clinical Multigene Testing for Prostate Cancer
    Tala Berro, Elizabeth Barrett, Saud H. AlDubayan
    Urologic Clinics of North America.2021; 48(3): 297.     CrossRef
  • Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
    Maria Adamaki, Vassilios Zoumpourlis
    Pharmacology & Therapeutics.2021; 228: 107932.     CrossRef
  • Observed evidence for guideline‐recommended genes in predicting prostate cancer risk from a large population‐based cohort
    Jun Wei, Wancai Yang, Zhuqing Shi, Lucy Lu, Qiang Wang, W. Kyle Resurreccion, Valentina Engelmann, S. Lilly Zheng, Peter J. Hulick, Kathleen A. Cooney, William B. Isaacs, Brian T. Helfand, Jim Lu, Jianfeng Xu
    The Prostate.2021; 81(13): 1002.     CrossRef
  • NBS1 I171V variant underlies individual differences in chromosomal radiosensitivity within human populations
    Keita Tomioka, Tatsuo Miyamoto, Silvia Natsuko Akutsu, Hiromi Yanagihara, Kazumasa Fujita, Ekaterina Royba, Hiroshi Tauchi, Takashi Yamamoto, Iemasa Koh, Eiji Hirata, Yoshiki Kudo, Masao Kobayashi, Satoshi Okada, Shinya Matsuura
    Scientific Reports.2021;[Epub]     CrossRef
  • Applications of Deep Learning and Fuzzy Systems to Detect Cancer Mortality in Next-Generation Genomic Data
    Cheng-Hong Yang, Sin-Hua Moi, Ming-Feng Hou, Li-Yeh Chuang, Yu-Da Lin
    IEEE Transactions on Fuzzy Systems.2021; 29(12): 3833.     CrossRef
  • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
    Veda N. Giri, Karen E. Knudsen, William K. Kelly, Heather H. Cheng, Kathleen A. Cooney, Michael S. Cookson, William Dahut, Scott Weissman, Howard R. Soule, Daniel P. Petrylak, Adam P. Dicker, Saud H. AlDubayan, Amanda E. Toland, Colin C. Pritchard, Curtis
    Journal of Clinical Oncology.2020; 38(24): 2798.     CrossRef
  • Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland
    Dominika Wokołorczyk, Wojciech Kluźniak, Tomasz Huzarski, Jacek Gronwald, Agata Szymiczek, Bogna Rusak, Klaudia Stempa, Katarzyna Gliniewicz, Aniruddh Kashyap, Sylwia Morawska, Tadeusz Dębniak, Anna Jakubowska, Marek Szwiec, Paweł Domagała, Jan Lubiński,
    International Journal of Cancer.2020; 147(10): 2793.     CrossRef
  • DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns
    Richa Sharma, Sara Lewis, Marcin W. Wlodarski
    Frontiers in Pediatrics.2020;[Epub]     CrossRef
  • Allelic modification of breast cancer risk in women with an NBN mutation
    Bogna Rusak, Wojciech Kluźniak, Dominika Wokołorczyk, Klaudia Stempa, Aniruddh Kashyap, Helena Rudnicka, Jacek Gronwald, Tomasz Huzarski, Tadeusz Dębniak, Anna Jakubowska, Marek Szwiec, Mohammad R. Akbari, Steven A. Narod, Jan Lubiński, Cezary Cybulski
    Breast Cancer Research and Treatment.2019; 178(2): 427.     CrossRef
  • 8,454 View
  • 300 Download
  • 20 Web of Science
  • 21 Crossref
Close layer
Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer
Sung Han Kim, Boram Park, Jae Young Joung, Jinsoo Chung, Ho Kyung Seo, Kang Hyun Lee, Weon Seo Park
Cancer Res Treat. 2019;51(3):910-918.   Published online October 2, 2018
DOI: https://doi.org/10.4143/crt.2018.314
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to determine whether histologic inflammation (HI) in initial and repeat prostate biopsy specimens was significantly associated with the detection of prostate cancer.
Materials and Methods
Between 2005 and 2017, the clinicopathological records of patients with high prostatespecific antigen (PSA) levels who underwent initial and repeat prostate biopsies were retrospectively reviewed. The presence of HI and its degree in each biopsied specimen were interpreted by one uropathologist with 20 years of experience. The association between HI and cancer diagnosis was statistically assessed, with p < 0.05 considered significant, and the cancer and non-cancer groups were compared.
Results
Among the 522 patients with a median PSA levels of 6.5 ng/dL, including 258 (49.4%) whose cancer was diagnosed following repeat biopsy, the median degrees of HI in the initial and repeat biopsies were 25.0% and 41.7%, respectively. Furthermore, 211 (40.4%) and 247 (47.3%) patients had HI (> 0%) on biopsied specimens, respectively. Comparison of the cancer and noncancer groups revealed that a greater rate of HI specimens in the initial biopsy was associated with fewer prostate cancer diagnoses following repeat biopsy (p < 0.001). Other comparisons between the cancer and non-cancer groups showed that the cancer group had a significantly higher rate of hypertension, whereas those non-cancer group had a significantly higher rate of benign prostatic hyperplasia and prostatitis (p < 0.05).
Conclusion
A finding of a lesser degree of HI in the initial and a greater degree of HI in the repeat biopsied specimens was associated with the higher probability of cancer diagnosis in patients with high PSA levels.

Citations

Citations to this article as recorded by  
  • Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
    Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S. Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A. Chitale, Deliang Tang, Andrew G. Rundle, Kenneth A. Iczkowski
    Cancer Medicine.2021; 10(9): 3013.     CrossRef
  • 6,205 View
  • 144 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Genome-Wide Association of Genetic Variation in the PSCA Gene with Gastric Cancer Susceptibility in a Korean Population
Boyoung Park, Sarah Yang, Jeonghee Lee, Hae Dong Woo, Il Ju Choi, Young Woo Kim, Keun Won Ryu, Young-Il Kim, Jeongseon Kim
Cancer Res Treat. 2019;51(2):748-757.   Published online September 5, 2018
DOI: https://doi.org/10.4143/crt.2018.162
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Half of the world’s gastric cancer cases and the highest gastric cancer mortality rates are observed in Eastern Asia. Although several genome-wide association studies (GWASs) have revealed susceptibility genes associated with gastric cancer, no GWASs have been conducted in the Korean population, which has the highest incidence of gastric cancer.
Materials and Methods
We performed genome scanning of 450 gastric cancer cases and 1,134 controls via Affymetrix Axiom Exome 319 arrays, followed by replication of 803 gastric cancer cases and 3,693 healthy controls.
Results
We showed that the rs2976394 in the prostate stem cell antigen (PSCA) gene is a gastriccancer-susceptibility gene in a Korean population, with genome-wide significance and an odds ratio (OR) of 0.70 (95% confidence interval [CI], 0.64 to 0.77). A strong linkage disequilibrium with rs2294008 was also found, indicating an association with susceptibility. Individuals with the CC genotype of the PSCA gene showed an approximately 2-fold lower risk of gastric cancer compared to those with the TT genotype (OR, 0.47; 95% CI, 0.39 to 0.57). The effect of the PSCA gene on gastric cancer was more prominent in the female population and for diffuse type gastric cancer.
Conclusion
Our result confirmed that the PSCA gene may be the most important susceptibility gene for gastric cancer risk in a Korean population.

Citations

Citations to this article as recorded by  
  • Functional Annotation and Gene Set Analysis of Gastric Cancer Risk Loci in a Korean Population
    Hyojin Pyun, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Joohon Sung, Jeongseon Kim
    Cancer Research and Treatment.2024; 56(1): 191.     CrossRef
  • HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer
    Ansley Gnanapragasam, Eftyhios Kirbizakis, Anna Li, Kyle H. White, Katelyn L. Mortenson, Juliana Cavalcante de Moura, Wajih Jawhar, Yifei Yan, Reilly Falter, Colleen Russett, Betty Giannias, Sophie Camilleri-Broët, Nicholas Bertos, Jonathan Cools-Lartigue
    Cancer Research.2024; 84(14): 2377.     CrossRef
  • High Polygenic Risk Scores Positively Associated with Gastric Cancer Risk Interact with Coffee and Polyphenol Intake and Smoking Status in Korean Adults
    Meiling Liu, Sang-Shin Song, Sunmin Park
    Nutrients.2024; 16(19): 3263.     CrossRef
  • Dietary mercury intake, the IL23R rs10889677 polymorphism, and the risk of gastric cancer in a Korean population: a hospital-based case-control study
    Ji Hyun Kim, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    Epidemiology and Health.2024; 46: e2024051.     CrossRef
  • Interaction between dietary potassium intake and TNF-α rs1800629 genetic polymorphism in gastric cancer risk: a case–control study conducted in Korea
    Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    British Journal of Nutrition.2023; 130(5): 887.     CrossRef
  • Rare variants confer shared susceptibility to gastrointestinal tract cancer risk
    Ji Zheng, Xin Wang, Jingrao Li, Yuanna Wu, Jiang Chang, Junyi Xin, Meilin Wang, Tianpei Wang, Qingyi Wei, Mengyun Wang, Ruoxin Zhang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The association of dietary fibre intake and the IL13 rs20541 polymorphism with the risk of gastric cancer: a case-control study in Korea
    Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    European Journal of Clinical Nutrition.2022; 76(7): 1031.     CrossRef
  • Systematic review of gastric cancer-associated genetic variants, gene-based meta-analysis, and gene-level functional analysis to identify candidate genes for drug development
    Sangjun Lee, Han-Kwang Yang, Hyuk-Joon Lee, Do Joong Park, Seong-Ho Kong, Sue K. Park
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Incidence of Hereditary Gastric Cancer May Be Much Higher than Reported
    Paula Baraúna de Assumpção, Paulo Pimentel de Assumpção, Fabiano Cordeiro Moreira, Ândrea Ribeiro-dos-Santos, Amanda F. Vidal, Leandro Magalhães, André Salim Khayat, André Maurício Ribeiro-dos-Santos, Giovanna C. Cavalcante, Adenilson Leão Pereira, Inácio
    Cancers.2022; 14(24): 6125.     CrossRef
  • Enhancing the Trajectories of Cancer Health Disparities Research: Improving Clinical Applications of Diversity, Equity, Inclusion, and Accessibility
    Rachel Martini, Endale Gebregzabher, Lisa Newman, Melissa B. Davis
    Cancer Discovery.2022; 12(6): 1428.     CrossRef
  • Identification of Novel Susceptible Genes of Gastric Cancer Based on Integrated Omics Data
    Huang Yaoxing, Yu Danchun, Sun Xiaojuan, Jiang Shuman, Yan Qingqing, Jia Lin
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • The Associations of Dietary Iron Intake and the Transferrin Receptor (TFRC) rs9846149 Polymorphism with the Risk of Gastric Cancer: A Case–Control Study Conducted in Korea
    Tao Thi Tran, Madhawa Gunathilake, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Jeongseon Kim
    Nutrients.2021; 13(8): 2600.     CrossRef
  • Integration of GWAS and eQTL Analysis to Identify Risk Loci and Susceptibility Genes for Gastric Cancer
    Jing Ni, Bin Deng, Meng Zhu, Yuzhuo Wang, Caiwang Yan, Tianpei Wang, Yaqian Liu, Gang Li, Yanbing Ding, Guangfu Jin
    Frontiers in Genetics.2020;[Epub]     CrossRef
  • Evolutionary History of the Risk of SNPs for Diffuse-Type Gastric Cancer in the Japanese Population
    Risa L. Iwasaki, Koji Ishiya, Hideaki Kanzawa-Kiriyama, Yosuke Kawai, Jun Gojobori, Yoko Satta
    Genes.2020; 11(7): 775.     CrossRef
  • TNF genetic polymorphism (rs1799964) may modify the effect of the dietary inflammatory index on gastric cancer in a case–control study
    Jeeeun Kim, Jeonghee Lee, Il Ju Choi, Young-Il Kim, Joohon Sung, Jeongseon Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • Prediction of gastric cancer risk: association between ZBTB20 genetic variance and gastric cancer risk in Chinese Han population
    Fei Bai, Ke Xiao
    Bioscience Reports.2020;[Epub]     CrossRef
  • Incidence of Stomach and Esophageal Cancers in Mongolia: Data from 2009 to 2018
    Tsegmed Sambuu, Nasanjargal Tumurbat, Bayar Davaa, Bolor-Erdene Tudev
    Euroasian Journal of Hepato-Gastroenterology.2020; 10(1): 16.     CrossRef
  • 10,315 View
  • 209 Download
  • 16 Web of Science
  • 17 Crossref
Close layer
Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database
Bum Sik Tae, Byung Jo Jeon, Seung Hun Shin, Hoon Choi, Jae Hyun Bae, Jae Young Park
Cancer Res Treat. 2019;51(2):593-602.   Published online July 18, 2018
DOI: https://doi.org/10.4143/crt.2018.119
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction.
Materials and Methods
Using the National Health Insurance Service database of the entire Korean adult prostate cancer population (n=236,391), data on ADT and cognitive dysfunction between 2008 and 2015 were analyzed. We excluded patients previously diagnosed with cognitive dysfunction, dementia, or a cerebral event history. We tested the effect of ADT on the risk of cognitive dysfunction using propensity score–matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. Our final cohort comprised of 35,401 individuals with prostate cancer, including 24,567 men (70.6%) who underwent ADT.
Results
During a mean follow-up period of 4.1 years, 4,741 patients were newly diagnosed with cognitive dysfunction. A statistically significant association was found between ADT and the risk of cognitive dysfunction (hazard ratio, 1.169; p=0.002). Meanwhile, age (≥ 70 years), diabetes, hypertension, cardiovascular history, and peripheral vascular disease were identified as factors that contribute to the increased risk of cognitive dysfunction. In contrast, the use of statins and aspirin was associated with a lower risk of cognitive dysfunction. Kaplan-Meier analysis demonstrated that patients aged 70 years or older who underwent ADT had the lowest cumulative probability of remaining cognitive dysfunction-free (log-rank p < 0.001).
Conclusion
Our results revealed an association between the use of ADT for the treatment of prostate cancer and an increased risk of cognitive dysfunction in a nationwide population-based study. This finding should be further evaluated in prospective studies.

Citations

Citations to this article as recorded by  
  • Unraveling the bidirectional link between cancer and dementia and the impact of cancer therapies on dementia risk: A systematic review and meta‐analysis
    Liwei Ma, Edwin C. K. Tan, Benjamin Goudey, Liang Jin, Yijun Pan
    Alzheimer's & Dementia.2025;[Epub]     CrossRef
  • Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis
    David E. Hinojosa-Gonzalez, Affan Zafar, Gal Saffati, Shane Kronstedt, Dimitar V. Zlatev, Mohit Khera
    Prostate Cancer and Prostatic Diseases.2024; 27(3): 507.     CrossRef
  • Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
    Viswanath Das, John H. Miller, Charanraj Goud Alladi, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch
    Medicinal Research Reviews.2024; 44(5): 2078.     CrossRef
  • Cognitive effects of long‐term androgen deprivation therapy in older men with prostate cancer
    Denise Pergolizzi, Kathleen R. Flaherty, Rebecca M. Saracino, James C. Root, Elizabeth Schofield, Caroline Cassidy, Vani Katheria, Sunita K. Patel, William Dale, Christian J. Nelson
    Psycho-Oncology.2024;[Epub]     CrossRef
  • Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review
    Lorna Pembroke, Kerry A. Sherman, Heather Francis, Haryana M. Dhillon, Howard Gurney, David Gillatt
    Neuropsychology Review.2024;[Epub]     CrossRef
  • Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration
    Chao Zhang, Mae Aida, Shalini Saggu, Haiyan Yu, Lianna Zhou, Hasibur Rehman, Kai Jiao, Runhua Liu, Lizhong Wang, Qin Wang
    Science Advances.2024;[Epub]     CrossRef
  • Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies
    Meng-fan Cui, Li-ming Chen, Cindy Jiang, Bing-zhe Ma, Fu-wen Yuan, Chen Zhao, Shi-min Liu
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Urogeriatrisches Denken am Beispiel der antiandrogenen Therapie des Prostatakarzinoms
    A. Wiedemann, A. Manseck, J. Stein, M. Fröhner, C. Fiebig, A. Piotrowski, R. Kirschner-Hermanns
    Die Urologie.2024; 63(9): 867.     CrossRef
  • Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease
    Rachel M. Barker, Alfie Chambers, Patrick G. Kehoe, Edward Rowe, Claire M. Perks
    Clinical Science.2024; 138(21): 1357.     CrossRef
  • A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors
    Charlotte Kerstens, Hans P. M. W. Wildiers, Gwen Schroyen, Mercedes Almela, Ruth E. Mark, Maarten Lambrecht, Sabine Deprez, Charlotte Sleurs
    Cancers.2023; 15(4): 1215.     CrossRef
  • Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
    Steven C. R. Williams, Ndaba Mazibuko, Owen O’Daly, Christian Zurth, Fiona Patrick, Christian Kappeler, Iris Kuss, Patricia E. Cole
    Targeted Oncology.2023; 18(3): 403.     CrossRef
  • Does ADT Influence the Risk of Suicidal Ideation among US Veteran Prostate Cancer Patients Pre-Exposed to PTSD?
    Smit Brahmbhatt, Herta H. Chao, Shiv Verma, Sanjay Gupta
    Cancers.2023; 15(10): 2739.     CrossRef
  • Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Jin Seon Cho
    Prostate International.2022; 10(1): 68.     CrossRef
  • Impact of Testosterone on Alzheimer’s Disease
    Vittorio Emanuele Bianchi
    The World Journal of Men's Health.2022; 40(2): 243.     CrossRef
  • Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
    Gregory L. Branigan, Georgina Torrandell‐Haro, Maira Soto, Edward P. Gelmann, Francesca Vitali, Kathleen E. Rodgers, Roberta Diaz Brinton
    Cancer Medicine.2022; 11(13): 2687.     CrossRef
  • Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
    Jeffrey S. Wefel, Charles J. Ryan, Julie Van, James C. Jackson, Alicia K. Morgans
    CNS Drugs.2022; 36(5): 419.     CrossRef
  • The Insignificant Correlation between Androgen Deprivation Therapy and Incidence of Dementia Using an Extension Survival Cox Hazard Model and Propensity-Score Matching Analysis in a Retrospective, Population-Based Prostate Cancer Registry
    Young Ae Kim, Su-Hyun Kim, Jae Young Joung, Min Soo Yang, Joung Hwan Back, Sung Han Kim
    Cancers.2022; 14(11): 2705.     CrossRef
  • Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
    David Conde-Estévez, Iván Henríquez, Jesús Muñoz-Rodríguez, Alejo Rodriguez-Vida
    Expert Opinion on Drug Metabolism & Toxicology.2022; 18(9): 601.     CrossRef
  • Testosterone and Alzheimer’s disease
    K. O. Kuznetsov, R. R. Khaidarova, R. H. Khabibullina, E. S. Stytsenko, V. I. Filosofova, I. R. Nuriakhmetova, E. M. Hisameeva, G. S. Vazhorov, F. R. Khaibullin, E. A. Ivanova, K. V. Gorbatova
    Problems of Endocrinology.2022; 68(5): 97.     CrossRef
  • Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis
    Haiying Cui, Yao Wang, Fei Li, Guangyu He, Zongmiao Jiang, Xiaokun Gang, Guixia Wang
    Prostate Cancer and Prostatic Diseases.2021; 24(1): 15.     CrossRef
  • Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors
    Alicia K. Morgans, Joseph Renzulli, Kara Olivier, Neal D. Shore
    Clinical Genitourinary Cancer.2021; 19(5): 467.e1.     CrossRef
  • Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
    Jui-Ming Liu, Chin-Yao Shen, Wallis C. Y. Lau, Shih-Chieh Shao, Kenneth K. C. Man, Ren-Jun Hsu, Chun-Te Wu, Edward Chia-Cheng Lai
    Cancers.2021; 13(15): 3861.     CrossRef
  • Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function
    A. B. Reiss, U. Saeedullah, D. J. Grossfeld, A. D. Glass, A. Pinkhasov, A. E. Katz
    Clinical and Translational Oncology.2021; 24(5): 733.     CrossRef
  • Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
    Vérane Achard, Kelly Ceyzériat, Benjamin B. Tournier, Giovanni B. Frisoni, Valentina Garibotto, Thomas Zilli
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
    Niamh L Mundell, Patrick J Owen, Jack Dalla Via, Helen Macpherson, Robin M Daly, Steve F Fraser
    BMJ Open.2021; 11(12): e058478.     CrossRef
  • Antiaging Therapies, Cognitive Impairment, and Dementia
    Devin Wahl, Rozalyn M Anderson, David G Le Couteur, Rafael de Cabo
    The Journals of Gerontology: Series A.2020; 75(9): 1643.     CrossRef
  • A review of prostate cancer treatment impact on the CNS and cognitive function
    Charles Ryan, Jeffrey S. Wefel, Alicia K. Morgans
    Prostate Cancer and Prostatic Diseases.2020; 23(2): 207.     CrossRef
  • Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea
    Young-Jae Hwang, Seon Mee Park, Soomin Ahn, Jongchan Lee, Young Soo Park, Nayoung Kim
    Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 575.     CrossRef
  • WITHDRAWN: The Changes of ADC Value, DCE-MRI Parameters and Their Influence on Neuropsychology in Prostate Cancer Patients after Endocrine Therapy Based on Magnetic Resonance Imaging
    Yang Lu, Shang Ge, Yan Liu, Gengji Bai
    Neuroscience Letters.2020; : 135221.     CrossRef
  • Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician
    Aisha L. Siebert, Leiszle Lapping-Carr, Alicia K. Morgans
    European Urology Focus.2020; 6(6): 1170.     CrossRef
  • An Updated Review: Androgens and Cognitive Impairment in Older Men
    Zhonglin Cai, Hongjun Li
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Seong Soo Jeon, Hanjong Ahn, Young-Su Ju, Jin Seon Cho, Gianluigi Forloni
    PLOS ONE.2020; 15(12): e0244660.     CrossRef
  • Androgen deprivation therapy for prostate cancer and risk of dementia
    David Robinson, Hans Garmo, Mieke Van Hemelrijck, Jan‐Erik Damber, Ola Bratt, Lars Holmberg, Lars‐Olof Wahlund, Pär Stattin, Jan Adolfsson
    BJU International.2019; 124(1): 87.     CrossRef
  • Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer
    Nirmish Singla, Rashed A. Ghandour, Ganesh V. Raj
    Expert Opinion on Investigational Drugs.2019; 28(3): 249.     CrossRef
  • Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis
    Omar Saeed, Lori J. Bernstein, Rouhi Fazelzad, Mary Samuels, Lynn A. Burmeister, Lehana Thabane, Shereen Ezzat, David P. Goldstein, Jennifer Jones, Anna M. Sawka
    Journal of Cancer Survivorship.2019; 13(2): 231.     CrossRef
  • Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
    Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park
    Cancer Medicine.2019; 8(9): 4475.     CrossRef
  • 9,419 View
  • 293 Download
  • 37 Web of Science
  • 36 Crossref
Close layer
Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study
Dong Wook Shin, Sang Hyub Lee, Tae-Hwan Kim, Seok Joong Yun, Jong Kil Nam, Seung Hyun Jeon, Seung Chol Park, Seung Il Jung, Jong-Hyock Park, Jinsung Park
Cancer Res Treat. 2019;51(2):556-567.   Published online July 16, 2018
DOI: https://doi.org/10.4143/crt.2018.221
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Health-related quality of life (HRQOL) information related to radical prostatectomy (RP) is valuable for prostate cancer (PC) patients needing to make treatment decisions. We aimed to investigate HRQOL change in PC patients who underwent three types of RP (open, laparoscopic, or robotic) and compared their HRQOL with that of general population.
Materials and Methods
Patients were prospectively recruited between October 2014 and December 2015. European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) and PC-specific module (PR25) were administered before surgery (baseline) and at postoperative 3 and 12 months. At each time point, HRQOL was compared, and a difference of 10 out of 0-100 scale was considered clinically significant.
Results
Among 258 screened patients, 209 (41 open, 63 laparoscopic, and 105 robotic surgeries) were included. Compared to baseline, physical, emotional, and cognitive functioning improved at 12 months. Role functioning worsened at 3 months, but recovered to baseline at 12 months. Pain, insomnia, diarrhea, and financial difficulties also significantly improved at 12 months. Most PR25 scales excluding bowel symptoms deteriorated at 3 months. Urinary symptoms and incontinence aid recovered at 12 months, whereas sexual activity and sexual function remained poor at 12 months. Clinically meaningful differences in HRQOL were not observed according to RP modalities. Compared to the general population, physical and role functioning were significantly lower at 3 months, but recovered by 12 months. Social functioning did not recover.
Conclusion
Most HRQOL domains showed recovery within 12 months after RP, excluding sexual functioning and social functioning. Our findings may guide patients considering surgical treatment for PC.

Citations

Citations to this article as recorded by  
  • Quality of life after robotic versus conventional minimally invasive cancer surgery: a systematic review and meta-analysis
    Russell Seth Martins, Asad Saulat Fatimi, Omar Mahmud, Muhammad Umar Mahar, Arshia Jahangir, Kinza Jawed, Shalni Golani, Ayra Siddiqui, Syed Roohan Aamir, Ali Ahmad
    Journal of Robotic Surgery.2024;[Epub]     CrossRef
  • The Effect of Discharge Education and Post-Discharge Telephone Counseling on Quality of Life in Patients Undergoing Radical Prostatectomy: A Randomized Controlled Study
    İpek Köse Tosunöz, Sevgi Deniz Doğan, Şeyma Yurtseven, Sevban Arslan
    Cukurova Anestezi ve Cerrahi Bilimler Dergisi.2024; 7(3): 205.     CrossRef
  • Health‐related quality of life the first year after a prostate cancer diagnosis a systematic review
    Louise Dorner Østergaard, Mads Hvid Poulsen, Malene Eiberg Jensen, Lars Lund, Malene Grubbe Hildebrandt, Birgitte Nørgaard
    International Journal of Urological Nursing.2023; 17(1): 15.     CrossRef
  • Quantitative Analysis of Quality of Life and Exploration of Influencing Factors in Patients Undergoing Radical Prostatectomy
    Feiyang Wang, Jiajun Chen, Weihao Wang, Mengyao Li, Chao Peng, Shouhua Pan, Chuanchuan Zhan, Keyuan Zhao, Yulei Li, Lulu Zhang, Gang Xu, Jing Jin
    Urology.2023; 181: 105.     CrossRef
  • Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial
    Josée Savard, Hanane Moussa, Jean‐François Pelletier, Pierre Julien, Louis Lacombe, Rabi Tiguert, Yves Caumartin, Thierry Dujardin, Paul Toren, Frédéric Pouliot, Michele Lodde, Yves Fradet, Karine Robitaille, Vincent Fradet
    Cancer Medicine.2023; 12(19): 20163.     CrossRef
  • Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study
    Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne
    Cancer Management and Research.2022; Volume 14: 1525.     CrossRef
  • A systematic review of supervised comprehensive functional physiotherapy after radical prostatectomy
    B. Steenstrup, M. Cartier, F.X. Nouhaud, G. Kerdelhue, M. Gilliaux
    Progrès en Urologie.2022; 32(7): 525.     CrossRef
  • Perioperative psychological issues and nursing care among patients undergoing minimally invasive surgeries
    Kehua Yang, Xu Shao, Xinghui Lv, Feimin Yang, Qunyan Shen, Jing Fang, Wei Chen
    Laparoscopic, Endoscopic and Robotic Surgery.2022; 5(3): 92.     CrossRef
  • A Survey on the Quality of Life of Prostate Cancer Patients in Korean Prostate Cancer Patients Association
    Yun-Sok Ha, Kwang Taek Kim, Wook Nam, Hongzoo Park, Sangjun Yoo, Chan Ho Lee, Ho Seok Chung, Woo Suk Choi, Jiyoun Kim, Jaeeun Shin, Jeong Hyun Kim, Cheol Kwak
    The Korean Journal of Urological Oncology.2022; 20(4): 265.     CrossRef
  • Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study
    Myung Soo Kim, Seung Il Jung, Ho Seok Chung, Eu Chang Hwang, Dongdeuk Kwon
    Prostate International.2021; 9(3): 132.     CrossRef
  • Quality of life assessment using EORTC QLQ questionnaires in the prostate cancer population treated with radical prostatectomy: a systematic review
    Tomasz Jurys, Jacek Durmala
    Scandinavian Journal of Urology.2021; 55(2): 90.     CrossRef
  • Évaluation de l’observance et de l’adhésion thérapeutique de deux protocoles de rééducation après prostatectomie
    Benoit Steenstrup, Claire Breton, Guillaume Galliou, François-Xavier Nouhaud
    Kinésithérapie, la Revue.2021; 21(234): 12.     CrossRef
  • Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy
    Yann Neuzillet, Mathieu Rouanne, Jean-François Dreyfus, Jean-Pierre Raynaud, Marc Schneider, Morgan Roupret, Sarah Drouin, Marc Galiano, Xavier Cathelinau, Thierry Lebret, Henry Botto
    Asian Journal of Andrology.2021; 23(4): 370.     CrossRef
  • The Effect of Post-prostatectomy Urinary Incontinence on Health-related Quality of Life in Patients with Prostate Cancer
    Jeong Hyun Kim, Yeon Soo Jang, Young Deuk Choi, Eui Geum Oh
    Korean Journal of Adult Nursing.2019; 31(3): 293.     CrossRef
  • Prostate-specific health-related quality of life and patient-physician communication — A 3.5-year follow-up
    Nicole Ernstmann, Jan Herden, Lothar Weissbach, André Karger, Kira Hower, Lena Ansmann
    Patient Education and Counseling.2019; 102(11): 2114.     CrossRef
  • 10,161 View
  • 294 Download
  • 14 Web of Science
  • 15 Crossref
Close layer
Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul
Jae Heon Kim, So Young Kim, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee
Cancer Res Treat. 2019;51(1):53-64.   Published online February 20, 2018
DOI: https://doi.org/10.4143/crt.2017.468
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aims to investigate the trend in medical travel by non-Seoul residents to Seoul for treatment of prostate cancer and also to investigate the possible factors affecting the trend.
Materials and Methods
This study represents a retrospective cohort study using data from theKoreanNationalHealth Insurance System from 2002 to 2015. Annual trends were produced for proportions of patients who traveled according to the age group, economic status and types of treatment. Multiple logistic analysiswas used to determine factors affecting surgeries at medical facilities in Seoul among the non-Seoul residents.
Results
A total of 68,543 patients were defined as newly diagnosed prostate cancer cohorts from 2005 to 2014. The proportion of patients who traveled to Seoul for treatment, estimated from cases with prostate cancer-related claims, decreased slightly over 9 years (28.0 at 2005 and 27.0 at 2014, p=0.02). The average proportion of medical travelers seeking radical prostatectomy increased slightly but the increase was not statistically significant (43.1 at 2005 and 45.4 at 2014, p=0.26). Income level and performance ofrobot-assisted radical prostatectomy were significant positive factors for medical travel to medical facilities in Seoul. Combined comorbidity diseases and year undergoing surgery were significant negative factors for medical travel to medical facilities in Seoul.
Conclusion
The general trend of patients travelling from outside Seoul for prostate cancer treatment decreased from 2005 to 2014. However, a large proportion of traveling remained irrespective of direct distance from Seoul.

Citations

Citations to this article as recorded by  
  • Relationship between patient outcomes and patterns of fragmented cancer care in older adults with gastric cancer: A nationwide cohort study in South Korea
    Dong-Woo Choi, Seungju Kim, Sun Jung Kim, Dong Wook Kim, Kwang Sun Ryu, Jae Ho Kim, Yoon-Jung Chang, Kyu-Tae Han
    Journal of Geriatric Oncology.2024; 15(2): 101685.     CrossRef
  • Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study
    Seong Cheol Kim, Seungbong Han, Ji Hyung Yoon, Sungchan Park, Kyung Hyun Moon, Sang Hyeon Cheon, Gyung-Min Park, Taekmin Kwon
    Investigative and Clinical Urology.2024; 65(2): 124.     CrossRef
  • Domestic medical travel from non-Seoul regions to Seoul for initial breast cancer treatment: a nationwide cohort study
    Jae Ho Jeong, Jinhong Jung, Hee Jeong Kim, Jong Won Lee, Beom-Seok Ko, Byung Ho Son, Kyung Hae Jung, Il Yong Chung
    Annals of Surgical Treatment and Research.2023; 104(2): 71.     CrossRef
  • Symptom Experiences before Medical Help-Seeking and Psychosocial Responses of Patients with Esophageal Cancer: A Qualitative Study
    Hui Ge, Liang Zhang, Xuanxuan Ma, Wen Li, Shuwen Li, Pranshu Sahgal
    European Journal of Cancer Care.2023; 2023: 1.     CrossRef
  • Cancer care patterns in South Korea: Types of hospital where patients receive care and outcomes using national health insurance claims data
    Dong‐Woo Choi, Sun Jung Kim, Seungju Kim, Dong Wook Kim, Wonjeong Jeong, Kyu‐Tae Han
    Cancer Medicine.2023; 12(13): 14707.     CrossRef
  • Regional disparities in the availability of cancer clinical trials in Korea
    Jieun Jang, Wonyoung Choi, Sung Hoon Sim, Sokbom Kang
    Epidemiology and Health.2023; 46: e2024006.     CrossRef
  • Do Patients Residing in Provincial Areas Transport and Spend More on Cancer Treatment in Korea?
    Woorim Kim, Kyu-Tae Han, Seungju Kim
    International Journal of Environmental Research and Public Health.2021; 18(17): 9247.     CrossRef
  • Time Trends for Prostate Cancer Incidence from 2003 to 2013 in South Korea: An Age-Period-Cohort Analysis
    Hyun Young Lee, Do Kyoung Kim, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Bora Lee, Jae Heon Kim
    Cancer Research and Treatment.2020; 52(1): 301.     CrossRef
  • Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015
    Hyun Young Lee, Suyeon Park, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Jae Heon Kim
    Yonsei Medical Journal.2019; 60(3): 257.     CrossRef
  • Why is Life Expectancy in Busan Shorter than in Seoul? Age and Cause-Specific Contributions to the Difference in Life Expectancy between Two Cities
    Young-Ho Khang, Jinwook Bahk
    Yonsei Medical Journal.2019; 60(7): 687.     CrossRef
  • 10,897 View
  • 229 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population
Sung Han Kim, Sohee Kim, Jae Young Joung, Whi-An Kwon, Ho Kyung Seo, Jinsoo Chung, Byung-Ho Nam, Kang Hyun Lee
Cancer Res Treat. 2018;50(4):1194-1202.   Published online December 21, 2017
DOI: https://doi.org/10.4143/crt.2017.484
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The use of prostate-specific antigen as a biomarker for prostate cancer (PC) has been controversial and is, therefore, not used by many countries in their national health screening programs. The biological characteristics of PC in East Asians including Koreans and Japanese are different from those in the Western populations. Potential lifestyle risk factors for PC were evaluated with the aim of developing a risk prediction model.
Materials and Methods
A total of 1,179,172 Korean men who were cancer free from 1996 to 1997, had taken a physical examination, and completed a lifestyle questionnaire, were enrolled in our study to predict their risk for PC for the next eight years, using the Cox proportional hazards model. The model’s performance was evaluated using the C-statistic and Hosmer‒Lemeshow type chi-square statistics.
Results
The risk prediction model studied age, height, body mass index, glucose levels, family history of cancer, the frequency of meat consumption, alcohol consumption, smoking status, and physical activity, which were all significant risk factors in a univariate analysis. The model performed very well (C statistic, 0.887; 95% confidence interval, 0.879 to 0.895) and estimated an elevated PC risk in patients who did not consume alcohol or smoke, compared to heavy alcohol consumers (hazard ratio [HR], 0.78) and current smokers (HR, 0.73) (p < 0.001).
Conclusion
This model can be used for identifying Korean and other East Asian men who are at a high risk for developing PC, as well as for cancer screening and developing preventive health strategies.

Citations

Citations to this article as recorded by  
  • To Drink or Not to Drink? Investigating Alcohol’s Impact on Prostate Cancer Risk
    Aris Kaltsas, Michael Chrisofos, Evangelos N. Symeonidis, Athanasios Zachariou, Marios Stavropoulos, Zisis Kratiras, Ilias Giannakodimos, Asterios Symeonidis, Fotios Dimitriadis, Nikolaos Sofikitis
    Cancers.2024; 16(20): 3453.     CrossRef
  • Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study
    Tao Thi Tran, Jeonghee Lee, Junetae Kim, Sun-Young Kim, Hyunsoon Cho, Jeongseon Kim
    BMC Public Health.2024;[Epub]     CrossRef
  • Combinations of lifestyle behaviors and cancer risk among Korean adults
    Ngoc Minh Luu, Thi Tra Bui, Thi Phuong Thao Tran, Thi Huyen Trang Nguyen, Jin-Kyoung Oh
    Scientific Reports.2023;[Epub]     CrossRef
  • Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies
    Sarah Al-Fayez, Ashraf El-Metwally
    Tobacco Induced Diseases.2023; 21(February): 1.     CrossRef
  • Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
    Taewon Hwang, Hyungseok Oh, Jung Ah Lee, Eo Jin Kim
    BMC Urology.2023;[Epub]     CrossRef
  • Association Between Red and Processed Meat Consumption and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis
    Saeedeh Nouri-Majd, Asma Salari-Moghaddam, Azadeh Aminianfar, Bagher Larijani, Ahmad Esmaillzadeh
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Alcohol and Prostate Cancer: Time to Draw Conclusions
    Amanda J. Macke, Armen Petrosyan
    Biomolecules.2022; 12(3): 375.     CrossRef
  • Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
    Yan Jin, Jae Hung Jung, Woong Kyu Han, Eu Chang Hwang, Yoonmi Nho, Narae Lee, Ji Eun Yun, Kwang Suk Lee, Sang Hyub Lee, Hakmin Lee, Su-Yeon Yu
    Investigative and Clinical Urology.2022; 63(3): 251.     CrossRef
  • Association between Relative Preference for Vegetables and Meat and Cancer Incidence in Korean Adults: A Nationwide Population-based Retrospective Cohort Study
    Ga-Eun Yie, An Na Kim, Hyun Jeong Cho, Minji Kang, Sungji Moon, Inah Kim, Kwang-Pil Ko, Jung Eun Lee, Sue K. Park
    Korean Journal of Community Nutrition.2021; 26(3): 211.     CrossRef
  • Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review
    Antonio Bandala-Jacques, Kevin Daniel Castellanos Esquivel, Fernanda Pérez-Hurtado, Cristobal Hernández-Silva, Nancy Reynoso-Noverón
    JMIR Cancer.2021; 7(3): e30430.     CrossRef
  • Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data
    Yohwan Yeo, Dong Wook Shin, Jungkwon Lee, Kyungdo Han, Sang Hyun Park, Keun Hye Jeon, Jungeun Shin, Aesun Shin, Jinsung Park
    Journal of Personalized Medicine.2021; 12(1): 2.     CrossRef
  • Lifestyles, health habits, and prostate cancer
    Tomoyuki Kawada
    Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1623.     CrossRef
  • Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer
    Okyaz Eminaga, Omran Al-Hamad, Martin Boegemann, Bernhard Breil, Axel Semjonow
    Health Informatics Journal.2020; 26(2): 945.     CrossRef
  • Tailored Biofunctionalized Biosensor for the Label-Free Sensing of Prostate-Specific Antigen
    Sachin Mishra, Eun-Seong Kim, Parshant Kumar Sharma, Zhi-Ji Wang, Sung-Hyun Yang, Ajeet Kumar Kaushik, Cong Wang, Yang Li, Nam-Young Kim
    ACS Applied Bio Materials.2020; 3(11): 7821.     CrossRef
  • A Study on Risk Factors of the Incidence of Prostate Cancer Using National Health Insurance Service: Effects of BMI on Age
    Hye Sim Kim, Tae Hwa Go, Dae Ryong Kang, Jae Hung Jung, Sung Won Kwon, Sae Chul Kim, Jae Mann Song, Hyun Chul Chung, Sang Baek Koh
    Journal of Health Informatics and Statistics.2019; 44(4): 410.     CrossRef
  • 10,205 View
  • 258 Download
  • 13 Web of Science
  • 15 Crossref
Close layer
Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin, and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea
Minyong Kang, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong
Cancer Res Treat. 2018;50(3):984-991.   Published online October 27, 2017
DOI: https://doi.org/10.4143/crt.2017.248
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to determine the impact of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), statin, and cyclooxygenase 2 (COX-2) inhibitor on the development of kidney, prostate, and urothelial cancers by analyzing the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) database.
Materials and Methods
Among a representative sample cohort of 1,025,340 participants in NHIS-NSC database in 2002, we extracted data of 799,850 individuals who visited the hospital more than once, and finally included 321,122 individuals aged 40 and older. Following a 1-year washout period between 2002 and 2003, we analyzed 143,870 (male), 320,861 and 320,613 individuals for evaluating the risk of prostate cancer, kidney cancer and urothelial cancer developments, respectively, during 10-year follow-up periods between 2004 and 2013. The medication group consisted of patients prescribed these drugs more than 60% of the time in 2003. To adjustfor various parameters of the patients, a multivariate Cox regression model was adopted.
Results
During 10-year follow-up periods between 2004 and 2013, 9,627 (6.7%), 1,107 (0.4%), and 2,121 (0.7%) patients were diagnosed with prostate cancer, kidney cancer, and urothelial cancer, respectively. Notably, multivariate analyses revealed that NSAIDs significantly increased the risk of prostate cancer (hazard ratio [HR], 1.35). Also, it was found that aspirin (HR, 1.28) and statin (HR, 1.55) elevated the risk of kidney cancer. No drugs were associated with the risk of urothelial cancer.
Conclusion
In sum, our study provides the valuable information for the impact of aspirin, NSAID, statin, and COX-2 inhibitor on the risk of prostate, kidney, and urothelial cancer development and its survival outcomes.

Citations

Citations to this article as recorded by  
  • Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis
    Tzu Shuang Chen, Hui Ying Liu, Yin Lun Chang, Yao Chi Chuang, Yen Ta Chen, Yu Li Su, Chun Chieh Huang, Yen Ting Wu, Hung Jen Wang, Hao Lun Luo
    The World Journal of Men's Health.2024; 42(3): 630.     CrossRef
  • Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database
    Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun
    The World Journal of Men's Health.2023; 41(1): 110.     CrossRef
  • Evaluation of statin use and renal cell carcinoma risk identifies sex-specific associations with RCC subtypes
    Irmina Maria Michalek, Rebecca E. Graff, Alejandro Sanchez, Toni K. Choueiri, Eunyoung Cho, Mark A. Preston, Kathryn M. Wilson
    Acta Oncologica.2023; 62(9): 988.     CrossRef
  • Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies
    Shaodi Ma, Weihang Xia, Birong Wu, Chenyu Sun, Yuemeng Jiang, Haixia Liu, Scott Lowe, Zhen Zhou, Peng Xie, Juan Gao, Linya Feng, Xianwei Guo, Guangbo Qu, Yehuan Sun
    European Journal of Clinical Pharmacology.2023; 79(11): 1475.     CrossRef
  • Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review
    Hwanik Kim, Jung Kwon Kim
    The World Journal of Men's Health.2022; 40(3): 412.     CrossRef
  • The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study
    Fei Chen, Peggy Wan, Lynne R. Wilkens, Loïc Le Marchand, Christopher A. Haiman
    Cancer Epidemiology, Biomarkers & Prevention.2022; 31(5): 999.     CrossRef
  • Aspirin and the risk of nondigestive tract cancers: An updated meta‐analysis to 2019
    Claudia Santucci, Silvano Gallus, Marco Martinetti, Carlo La Vecchia, Cristina Bosetti
    International Journal of Cancer.2021; 148(6): 1372.     CrossRef
  • Association between depression and risk of Parkinson's disease in South Korean adults
    Wonjeong Jeong, Hyunkyu Kim, Jae Hong Joo, Sung-In Jang, Eun-Cheol Park
    Journal of Affective Disorders.2021; 292: 75.     CrossRef
  • Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment
    Bo Fan, Alradhi Mohammed, Yuanbin Huang, Hong Luo, Hongxian Zhang, Shenghua Tao, Weijiao Xu, Qian Liu, Tao He, Huidan Jin, Mengfan Sun, Man Sun, Zhifei Yun, Rui Zhao, Guoyu Wu, Xiancheng Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study
    Luyang Liu, Chao Sheng, Zhangyan Lyu, Hongji Dai, Kexin Chen
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study
    Charlotte Skriver, Christian Dehlendorff, Michael Borre, Klaus Brasso, Signe Benzon Larsen, Anne Tjønneland, Anton Pottegård, Jesper Hallas, Henrik Toft Sørensen, Søren Friis
    Cancer Causes & Control.2020; 31(2): 139.     CrossRef
  • Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors
    Shipra Gandhi, Manu Pandey, Nischala Ammannagari, Chong Wang, Mark J Bucsek, Lamya Hamad, Elizabeth Repasky, Marc S Ernstoff
    Immunotherapy.2020; 12(2): 141.     CrossRef
  • Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis
    Michael M Ward, Sara Alehashemi
    Rheumatology.2020; 59(12): 3817.     CrossRef
  • Complex roles of the old drug aspirin in cancer chemoprevention and therapy
    Hui Hua, Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang
    Medicinal Research Reviews.2019; 39(1): 114.     CrossRef
  • Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform
    Chang Wook Jeong, Jungyo Suh, Hyeong Dong Yuk, Bum Sik Tae, Miso Kim, Bhumsuk Keam, Jin Ho Kim, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim, Kyung Chul Moon, Gi Jeong Cheon, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak
    Investigative and Clinical Urology.2019; 60(4): 235.     CrossRef
  • The impact of acute inflammation on progression and metastasis in pancreatic cancer animal model
    Keun Soo Ahn, Ji Yeon Hwang, Ho-Seong Han, Sang Tae Kim, Ilseon Hwang, Young-Ok Chun
    Surgical Oncology.2018; 27(1): 61.     CrossRef
  • Prostate cancer multifocality, the index lesion, and the microenvironment
    Rafael R. Tourinho-Barbosa, Jean de la Rosette, Rafael Sanchez-Salas
    Current Opinion in Urology.2018; 28(6): 499.     CrossRef
  • Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis
    Zhenhua Shang, Xue Wang, Hao Yan, Bo Cui, Qi Wang, Jiangtao Wu, Xin Cui, Jin Li, Tongwen Ou, Kun Yang
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • 11,367 View
  • 330 Download
  • 17 Web of Science
  • 18 Crossref
Close layer
Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy
Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Seong Soo Jeon, Seong Il Seo, Hyun Moo Lee, Hanjong Ahn, Dong Deuk Kwon, Hong Koo Ha, Tae Gyun Kwon, Jae Seung Chung, Cheol Kwak, Hyung Jin Kim
Cancer Res Treat. 2018;50(1):265-274.   Published online April 14, 2017
DOI: https://doi.org/10.4143/crt.2016.477
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Korean patients with prostate cancer (PC) typically present with a more aggressive disease than patients in Western populations. Consequently, it is unclear if the current criteria for active surveillance (AS) can safely be applied to Korean patients. Therefore, this study was conducted to define appropriate selection criteria for AS for patients with PC in Korea.
Materials and Methods
We conducted a multicenter retrospective study of 2,126 patients with low risk PC who actually underwent radical prostatectomy. The primary outcome was an unfavorable disease, which was defined by non-organ confined disease or an upgrading of the Gleason score to ≥ 7 (4+3). Predictive variables of an unfavorable outcome were identified by multivariate analysis using randomly selected training samples (n=1,623, 76.3%). We compared our selected criteria to various Western criteria for the primary outcome and validated our criteria using the remaining validation sample (n=503, 23.7%).
Results
A non-organ confined disease rate of 14.9% was identified, with an increase in Gleason score ≥ 7 (4+3) of 8.7% and a final unfavorable disease status of 20.8%. The following criteria were selected: Gleason score ≤ 6, clinical stage T1-T2a, prostate-specific antigen (PSA) ≤ 10 ng/mL, PSA density < 0.15 ng/mL/mL, number of positive cores ≤ 2, and maximum cancer involvement in any one core ≤ 20%. These criteria provided the lowest unfavorable disease rate (11.7%) when compared to Western criteria (13.3%-20.7%), and their validity was confirmed using the validation sample (5.9%).
Conclusion
We developed AS criteria which are appropriate for Korean patients with PC. Prospective studies using these criteria are now warranted.

Citations

Citations to this article as recorded by  
  • Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN)
    Takuma Kato, Ryuji Matsumoto, Akira Yokomizo, Yoichiro Tohi, Hiroshi Fukuhara, Yoichi Fujii, Keiichiro Mori, Takuma Sato, Junichi Inokuchi, Katsuyoshi Hashine, Shinichi Sakamoto, Hidefumi Kinoshita, Koji Inoue, Toshiki Tanikawa, Takanobu Utsumi, Takayuki
    BJU International.2024; 134(4): 652.     CrossRef
  • Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry
    Chris Bangma, Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer, Jozien Helleman, Monique J. Roobol, Mikio Sugimoto, Byung Ha Chung, Lui Shiong Lee, Mark Frydenberg, Laurence Klotz, Michael Peacock, Antoinette Perry, Anders Bjartell, Antti Rannikko, Mi
    European Urology Oncology.2024;[Epub]     CrossRef
  • Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database
    Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun
    The World Journal of Men's Health.2023; 41(1): 110.     CrossRef
  • The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
    Chang Wook Jeong
    Journal of Urologic Oncology.2023; 21(2): 97.     CrossRef
  • Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
    Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
    Investigative and Clinical Urology.2022; 63(2): 175.     CrossRef
  • Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk
    Yasmine Amrousy, Hesham Haffez, Doaa Abdou, Hanaa Atya
    Molecular Medicine Reports.2022;[Epub]     CrossRef
  • A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
    Sang Hun Song, Jung Kwon Kim, Hakmin Lee, Sangchul Lee, Sung Kyu Hong, Seok-Soo Byun
    Investigative and Clinical Urology.2021; 62(1): 32.     CrossRef
  • The clinical impact of strict criteria for active surveillance of prostate cancer in Korean population: Results from a prospective cohort
    Jungyo Suh, Hyeong Dong Yuk, Minyong Kang, Bum Sik Tae, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong
    Investigative and Clinical Urology.2021; 62(4): 430.     CrossRef
  • Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
    Kerri Beckmann, Aida Santaolalla, Jozien Helleman, Peter Carroll, Byung Ha Chung, Lui Shiong Lee, Antoinette Perry, Jose Rubio-Briones, Mikio Sugimoto, Bruce Trock, Riccardo Valdagni, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage, Bruce Trock, Beh
    European Urology Open Science.2021; 34: 47.     CrossRef
  • Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance
    Juhyun Park, Sangjun Yoo, Min Chul Cho, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Hyeon Jeong
    Urologia Internationalis.2020; 104(3-4): 199.     CrossRef
  • Current status and progress of focal therapy in Asia
    Takumi Shiraishi, Osamu Ukimura
    Current Opinion in Urology.2018; 28(6): 529.     CrossRef
  • The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis
    Kun Liu, Shuo Gu, Xuzhong Liu, Qing Sun, Yunyan Wang, Junsong Meng, Zongyuan Xu
    Oncotarget.2017; 8(42): 72933.     CrossRef
  • 9,131 View
  • 249 Download
  • 9 Web of Science
  • 12 Crossref
Close layer
Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses
Kyo Chul Koo, Jin Seon Cho, Woo Jin Bang, Seung Hwan Lee, Sung Yong Cho, Sun Il Kim, Se Joong Kim, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
Cancer Res Treat. 2018;50(1):129-137.   Published online March 8, 2017
DOI: https://doi.org/10.4143/crt.2017.004
AbstractAbstract PDFPubReaderePub
Purpose
Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded conflicting results. Therefore, we used propensity score-matched analysis and competing risk regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality (OCM) between these two treatments.
Materials and Methods
The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028 patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT (n=507) between 2000 and 2016. RT±ADT cases (n=339) were matched with an equal number of RP cases by propensity scoring based on age, preoperative prostate-specific antigen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI). CSM and OCM were co-primary endpoints.
Results
Median follow-up was 65.0 months. Five-year overall survival rates for patients treated with RP and RT±ADT were 94.7% and 92.0%, respectively (p=0.105). Cumulative incidence estimates revealed comparable CSM rates following both treatments within all National Comprehensive Cancer Network risk groups. Gleason score ≥ 8 was associated with higher risk of CSM (p=0.009). OCM rates were comparable between both groups in the low- and intermediate-risk categories (p=0.354 and p=0.643, respectively). For high-risk patients, RT±ADT resulted in higher OCM rates than RP (p=0.011). Predictors of OCM were age ≥ 75 years (p=0.002) and CCI ≥ 2 (p < 0.001).
Conclusion
RP and RT±ADT provide comparable CSM outcomes in patients with localized or locally advanced PCa. The risk of OCM may be higher for older high-risk patients with significant comorbidities.

Citations

Citations to this article as recorded by  
  • External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study
    Caroline M. van der Starre, Chris H. Bangma, Maarten J. Bijlsma, Alfons C.M. van den Bergh, Lambertus A.L.M. Kiemeney, Wietske Kievit, Kees Vos, Diederik M. Somford, Sally M. Wildeman, Katja K.H. Aben, Igle J. de Jong, Floris J. Pos, Berdine L. Heesterman
    BMC Cancer.2025;[Epub]     CrossRef
  • Japanese clinical practice guidelines for prostate cancer 2023
    Yasuo Kohjimoto, Hiroji Uemura, Masahiro Yoshida, Shiro Hinotsu, Satoru Takahashi, Tsutomu Takeuchi, Kazuhiro Suzuki, Hiroshi Shinmoto, Tsutomu Tamada, Takahiro Inoue, Mikio Sugimoto, Atsushi Takenaka, Tomonori Habuchi, Hitoshi Ishikawa, Takashi Mizowaki,
    International Journal of Urology.2024; 31(11): 1180.     CrossRef
  • Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
    Berdine L. Heesterman, Katja K. H. Aben, Igle Jan de Jong, Floris J. Pos, Olga L. van der Hel
    BMC Cancer.2023;[Epub]     CrossRef
  • Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study
    Jun Seop Kim, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Change Jeong, Seong Il Seo, Hyun Moo Lee, Seong Soo Jeon
    Journal of Yeungnam Medical Science.2023; 40(4): 412.     CrossRef
  • Comparison of contrast-enhanced ultrasound targeted biopsies versus standard systematic biopsies for prostate cancer correction in different PSA value groups in rural China
    Dian Yuan Lu, Lan Liu, Li Shen, Jian Rong Cai, Li Xu, Li Hua Xiang
    Clinical Hemorheology and Microcirculation.2021; 77(3): 295.     CrossRef
  • Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis
    Benjamin A. Greenberger, Nicholas G. Zaorsky, Robert B. Den
    European Urology Focus.2020; 6(2): 404.     CrossRef
  • Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system
    Kyo Chul Koo, Kwang Suk Lee, Suah Kim, Choongki Min, Gyu Rang Min, Young Hwa Lee, Woong Kyu Han, Koon Ho Rha, Sung Joon Hong, Seung Choul Yang, Byung Ha Chung
    World Journal of Urology.2020; 38(10): 2469.     CrossRef
  • Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer
    Benjamin A. Greenberger, James M. Taylor, Victor E. Chen, Robert B. Den
    The Cancer Journal.2020; 26(1): 29.     CrossRef
  • Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis
    Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Masahiro Yao, Yuki Mukai, Madoka Sugiura, Shoko Takano, Eiko Ito, Hisashi Kaizu, Izumi Koike, Masaharu Hata, Masataka Taguri, Yasuhide Miy
    World Journal of Urology.2020; 38(10): 2477.     CrossRef
  • Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
    Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, Giorgio Gandaglia, Nicola Fossati, Brian Kelly, Raj Pal, Erik Briers, Philip Cornford, Maria De Santis, Stefano Fanti, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Thomas B.L. Lam, Michael Lar
    European Urology.2020; 77(5): 614.     CrossRef
  • Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer
    Satoru Taguchi, Kenshiro Shiraishi, Hiroshi Fukuhara
    Japanese Journal of Clinical Oncology.2020; 50(9): 963.     CrossRef
  • Comparing effectiveness of radical prostatectomy versus external beam radiotherapy in patients with locally advanced prostate cancer
    Xianghong Zhou, Kun Jin, Shi Qiu, Di Jin, Xinyang Liao, Xiang Tu, Xiaonan Zheng, Jiakun Li, Lu Yang, Qiang Wei
    Medicine.2020; 99(34): e21642.     CrossRef
  • Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatectomy and radiotherapy treatment
    Allan ‘Ben’ Smith, Orlando Rincones, Mark Sidhom, Pascal Mancuso, Karen Wong, Megan Berry, Dion Forstner, Leslie Bokey, Afaf Girgis
    Patient Education and Counseling.2019; 102(7): 1364.     CrossRef
  • Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis
    Changhoon Song, Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Seok-Soo Byun, Choung-Soo Kim, Sang Eun Lee, Jae-Sung Kim, Christopher J.D. Wallis
    PLOS ONE.2019; 14(4): e0215057.     CrossRef
  • 125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer
    Zhien Zhou, Weigang Yan, Yi Zhou, Fuquan Zhang, Hanzhong Li, Zhigang Ji
    Oncology Letters.2019;[Epub]     CrossRef
  • Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy
    Do Kyung Kim, Kyo Chul Koo, Kwang Suk Lee, Yoon Soo Hah, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • 9,809 View
  • 347 Download
  • 17 Web of Science
  • 16 Crossref
Close layer
Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry
Kwang Suk Lee, Kyo Chul Koo, In Young Choi, Ji Youl Lee, Jun Hyuk Hong, Choung-Soo Kim, Hyun Moo Lee, Sung Kyu Hong, Seok-Soo Byun, Koon Ho Rha, Byung Ha Chung
Cancer Res Treat. 2018;50(1):88-94.   Published online March 7, 2017
DOI: https://doi.org/10.4143/crt.2016.494
AbstractAbstract PDFPubReaderePub
Purpose
The present study aimed to re-stratify patients with high-risk prostate cancer according to the National Comprehensive Cancer Network guidelines among patients who underwent radical prostatectomy (RP).
Materials and Methods
This study used the Korean Prostate Cancer Database registry and identified 1,060 patients with high-risk prostate cancer who underwent RP between May 2001 and April 2013. All patients were categorized into risk groups, and subgroups were identified according to the type and number of high-risk factors.
Results
Of the 1,060 high-risk patients, 599 (56.5%), 408 (38.5%), and 53 (5.0%) had 1, 2, and 3 risk factors, respectively. In multivariate analysis, the Gleason score, percentage of positive biopsy cores, and number of risk factors present were identified as independent predictors of biochemical recurrence. There were significant differences in the 5-year postoperative biochemical failure-free survival (BCFFS) rate among the different high-risk factor subgroups (log-rank p < 0.001). There were no significant differences in the BCFFS rate between the subgroup of high-risk patients with a prostate-specific antigen level > 20 ng/mL alone and the intermediate-risk group with all factors (log-rank p=0.919 and p=0.781, respectively). Additionally, no significant differencewas noted in the BCFFS rate between high-risk patients having all factors and those in the very-high-risk group (p=0.566).
Conclusion
We successfully re-stratified patients with high-risk prostate cancer and identified the combinations of high-risk criteria that will help in the selection of patients for RP.

Citations

Citations to this article as recorded by  
  • Prostate‑specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high‑risk and very high‑risk prostate cancer
    Cheng-Kuang Yang, Chi-Rei Yang, Yen-Chuan Ou, Chen-Li Cheng, Hao-Chung Ho, Kun-Yuan Chiu, Shian-Shiang Wang, Jian-Ri Li, Chuan-Shu Chen, Chi-Feng Hung, Cheng-Che Chen, Shu-Chi Wang, Chia-Yen Lin, Sheng-Chun Hung
    Oncology Letters.2023;[Epub]     CrossRef
  • Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations
    Lei Zhang, Xiaoyan Liu, Rong Xia, Fei Chen, Xin Wang, Jia Bao, Yongzhao Shao, Xian Lu, Yan Wang, Jili Wang, May Thu Tun, Jonathan Melamed, Hebert Lepor, Fang-Ming Deng, Dongwen Wang, Guoping Ren
    Pathology - Research and Practice.2022; 234: 153933.     CrossRef
  • Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer
    Christian Ekanger, Svein Inge Helle, Daniel Heinrich, Dag Clement Johannessen, Ása Karlsdóttir, Yngve Nygård, Ole Johan Halvorsen, Lars Reisæter, Rune Kvåle, Liv Bolstad Hysing, Olav Dahl
    Advances in Radiation Oncology.2020; 5(3): 396.     CrossRef
  • 9,491 View
  • 248 Download
  • 4 Web of Science
  • 3 Crossref
Close layer
Bcl-2 as a Predictive Factor for Biochemical Recurrence after Radical Prostatectomy: An Interim Analysis
In-Chang Cho, Han Soo Chung, Kang Su Cho, Jeong Eun Kim, Jae Young Joung, Ho Kyung Seo, Jinsoo Chung, Weon Seo Park, Eun Kyung Hong, Kang Hyun Lee
Cancer Res Treat. 2010;42(3):157-162.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.157
AbstractAbstract PDFPubReaderePub
Purpose

The objective of this study was to determine Bcl-2 expression in localized prostate cancer and its potential role as a predictive factor for biochemical recurrence (BCR).

Materials and Methods

This study included 171 Korean patients with newly diagnosed adenocarcinoma of the prostate who underwent radical prostatectomy (RP) without neoadjuvant therapy at a single center between February 2005 and May 2009. RP specimens obtained from these patients were analyzed for the expression of Bcl-2 using tissue microarray. The values of Bcl-2 and other clinicopathologic factors were evaluated. Statistical analysis was performed with contingency table analysis, chi-square tests, and a Cox proportional hazard model.

Results

Bcl-2 expression was immunohistologically-confirmed in 42 patients (24.6%). Bcl-2 expression was not associated with conventional clinicopathologic factors. Bcl-2 negative patients had a significantly longer mean BCR-free survival than Bcl-2-positive patients (p=0.036). Among several variables, a high Gleason score in the RP specimen (≥8), extraprostatic extension, seminal vesicle invasion (SVI), lymphovascular invasion (LVI), and Bcl-2 expression were significant predictors of BCR based on univariate analysis. Multivariate Cox proportional hazards analysis revealed that BCR was significantly associated with a high prostate specific antigen level (p=0.047), SVI (p<0.001), a positive surgical margin (p=0.004) and Bcl-2 expression (p=0.012).

Conclusion

Bcl-2 expression in RP specimens is associated with a significantly worse outcome, suggesting a potential clinical role for Bcl-2. Post-operative Bcl-2 could be a significant predictor of outcome after RP.

Citations

Citations to this article as recorded by  
  • Association of Lymphovascular Invasion with Biochemical Recurrence and Adverse Pathological Characteristics of Prostate Cancer: A Systematic Review and Meta-analysis
    Jakub Karwacki, Marcel Stodolak, Andrzej Dłubak, Łukasz Nowak, Adam Gurwin, Kamil Kowalczyk, Paweł Kiełb, Nazar Holdun, Wojciech Szlasa, Wojciech Krajewski, Agnieszka Hałoń, Anna Karwacka, Tomasz Szydełko, Bartosz Małkiewicz
    European Urology Open Science.2024; 69: 112.     CrossRef
  • Immunohistochemical Expression of MDM2, Bcl-2, SATB2 and Ki-67 in Histological Variants of Unicystic Ameloblastoma
    Koustubh Amol Surana, Deepak Pandiar, Reshma Poothakulath Krishnan
    Head and Neck Pathology.2024;[Epub]     CrossRef
  • Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
    Daniel Westaby, Juan M. Jimenez-Vacas, Ana Padilha, Andreas Varkaris, Steven P. Balk, Johann S. de Bono, Adam Sharp
    Cancers.2021; 14(1): 51.     CrossRef
  • miR-205: A Potential Biomedicine for Cancer Therapy
    Neeraj Chauhan, Anupam Dhasmana, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
    Cells.2020; 9(9): 1957.     CrossRef
  • Bcl‐2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas
    Jue Young Kim, Jinsun Kim, Shadavlonjid Bazarsad, In‐Ho Cha, Sung‐Won Cho, Jin Kim
    Oral Diseases.2019; 25(4): 1158.     CrossRef
  • Tumor-Specific Induction of the Intrinsic Apoptotic Pathway—A New Therapeutic Option for Advanced Prostate Cancer?
    Philipp Wolf
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
    Norelia Torrealba, Gonzalo Rodriguez-Berriguete, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Sánchez-Chapado, Ricardo Paniagua, Mar Royuela
    The Aging Male.2018; 21(3): 211.     CrossRef
  • Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies
    Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuefang Jiang, Jun Yuan
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features
    Wei Jiang, Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Yuan Jun, Yuefang Jiang
    Medicine.2018; 97(49): e13537.     CrossRef
  • Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración
    R.F. Velázquez-Macías, F.E. De La Torre-Rendón, G. Ramos-Rodríguez, C.A. Calzada-Mendoza, R.M. Coral-Vázquez
    Revista Mexicana de Urología.2016; 76(5): 288.     CrossRef
  • Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research
    AKIRA KOMIYA, TOMONORI KATO, TAKASHI HORI, JUNYA FUKUOKA, KENJI YASUDA, HIDEKI FUSE
    International Journal of Oncology.2014; 44(1): 195.     CrossRef
  • MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer
    BERLINDA VERDOODT, MATTHIAS NEID, MARKUS VOGT, VIKTORIA KUHN, SVEN-THORSTEN LIFFERS, REIN-JÜRI PALISAAR, JOACHIM NOLDUS, ANDREA TANNAPFEL, ALIREZA MIRMOHAMMADSADEGH
    International Journal of Oncology.2013; 43(1): 307.     CrossRef
  • 9,288 View
  • 61 Download
  • 12 Crossref
Close layer
Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea
Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Jungshin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn
Cancer Res Treat. 2010;42(1):12-17.   Published online March 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.1.12
AbstractAbstract PDFPubReaderePub
Purpose

To assess the efficacy and safety of treating Korean patients with metastatic hormone-refractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.

Materials and Methods

This was a retrospective cohort study performed in 98 patients with metastatic HRPC between October 2003 and April 2008. After screening, 72 patients fit the eligibility criteria for inclusion in this study. Treatment consisted of 5 mg prednisolone twice daily and 75 mg/m2 docetaxel once every 3 weeks.

Results

Patient demographic characteristics included: median age 67 years (range, 51~86), median ECOG performance status 1 (0~2), Gleason score ≥8 in 61 patients (86%), and median serum PSA 45.5 ng/mL (range, 3.7~2,420.0). A total of 405 cycles of treatment were administered with a median 6 cycles (range, 1~20) per patient. The median docetaxel dose-intensity was 24.4 mg/m2/week (range, 17.5~25.6). A PSA response was seen in 51% of 63 evaluable patients at 12 weeks and maximal PSA decline ≥50% in 59% of 70 evaluable patients. Tumor response was evaluated in 13 patients, 4 patients achieved PR, and 5 patients had SD with a response rate of 31%. With a median follow-up duration of 23.1 months (95%CI, 16.7~29.5), the median time to PSA progression was 5.1 months (95%CI, 4.5~5.8) and median overall survival was 22.8 months (95%CI, 16.6~29.1). Nine (13%) patients experienced grade 3 or higher febrile neutropenia.

Conclusion

This chemotherapy regimen (docetaxel every 3 weeks plus prednisolone daily) demonstrated a strong response in Korean patients with metastatic HRPC, while the toxicity profile was manageable and similar to that observed in Western patients.

Citations

Citations to this article as recorded by  
  • Modulation of inflammatory mediators underlies the antitumor effect of the combination of morusin and docetaxel on prostate cancer cells
    Sana A. Fadil, Dina A.I. Albadawi, Khalid Z. Alshali, Hossam M. Abdallah, Mona M. Saber
    Biomedicine & Pharmacotherapy.2024; 180: 117572.     CrossRef
  • Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
    Kwonoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Hyo Jin Lee, Jae Lyun Lee
    Yonsei Medical Journal.2023; 64(2): 86.     CrossRef
  • Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer
    Bumjin Lim, Wonchul Lee, Yoon Soo Kyung, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
    Journal of Cancer Research and Clinical Oncology.2022; 148(3): 727.     CrossRef
  • AN INDIAN PROSPECTIVE STUDY OF DOCETAXEL THERAPY IN CRPC: CAN PRETREATMENT FACTORS PREDICT THE RESPONSE
    Devashish Kaushal, Rajeev Sood
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 78.     CrossRef
  • A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
    Seonggyu Byeon, Hongsik Kim, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Soon Il Lee, Se Hoon Park
    BMC Cancer.2021;[Epub]     CrossRef
  • Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
    Myung-Won Lee, Hyewon Ryu, Ik-Chan Song, Hwan-Jung Yun, Deog-Yeon Jo, Young Bok Ko, Hyo-Jin Lee
    Medicine.2020; 99(17): e19931.     CrossRef
  • A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
    Sang Eun Yoon, Youjin Kim, Jangho Cho, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byoung Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Su Jin Lee, Se Hoon Park
    BMC Urology.2019;[Epub]     CrossRef
  • Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells
    Chongyi Yang, Weijie Zhang, Jie Wang, Pengpeng Chen, Jiangjiang Jin
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer
    Hiromi Sato, Shintaro Narita, Norihiko Tsuchiya, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Kyoko Nomura, Tomonori Habuchi
    BMC Urology.2018;[Epub]     CrossRef
  • A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
    Hae Su Kim, Ji Yun Lee, Su Jin Lee, Ho Yeong Lim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Se Hoon Park
    BMC Urology.2017;[Epub]     CrossRef
  • Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
    Dong Hoon Lee, Jung Ho Kim, Won Ik Seo, Jong Kil Nam, Tae Nam Kim, Cheol Kyu Oh, Soo Dong Kim, Sung-Woo Park, Jae Sung Chung, Sang Hyun Park, Wan Lee, Gyung Tak Sung, Moon Kee Chung, Jae Il Chung
    The Korean Journal of Urological Oncology.2017; 15(2): 59.     CrossRef
  • Hormonal therapy and chemotherapy for advanced prostate cancer
    Jae Lyun Lee
    Journal of the Korean Medical Association.2015; 58(1): 30.     CrossRef
  • Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
    J-L Lee, J-H Ahn, M K Choi, Y Kim, S-W Hong, K-H Lee, I-G Jeong, C Song, B-S Hong, J H Hong, H Ahn
    British Journal of Cancer.2014; 110(10): 2472.     CrossRef
  • Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
    Jae-Lyun Lee, Se Hoon Park, Su-Jin Koh, Se Hoon Lee, Yu Jung Kim, Yoon Ji Choi, Jihye Lee, Ho Yeong Lim
    Cancer Chemotherapy and Pharmacology.2014; 74(5): 1005.     CrossRef
  • Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer
    Whi-An Kwon, Tae Hoon Oh, Jae Whan Lee, Seung Chol Park
    Asian Pacific Journal of Cancer Prevention.2014; 15(8): 3443.     CrossRef
  • Clinical predictor of survival following docetaxel-based chemotherapy
    HSIANG-YING LEE, WEN-JENG WU, CHUN-HSIUNG HUANG, YII-HER CHOU, CHUN-NUNG HUANG, YUNG-CHIN LEE, KAI-FU YANG, MEI-HUI LEE, SHU-PIN HUANG
    Oncology Letters.2014; 8(4): 1788.     CrossRef
  • Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
    Geehyun Song, Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
    Prostate International.2013; 1(3): 125.     CrossRef
  • Quimioterapia sistémica basada en docetaxel en hombres coreanos mayores con cáncer de próstata resistente a la castración
    S.C.H. Park, L.J. Whan, R.J. Sik
    Actas Urológicas Españolas.2012; 36(7): 425.     CrossRef
  • Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer
    S.C.H. Park, L.J. Whan, R.J. Sik
    Actas Urológicas Españolas (English Edition).2012; 36(7): 425.     CrossRef
  • 11,600 View
  • 73 Download
  • 19 Crossref
Close layer
Review Article
Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges
Richard Choo
Cancer Res Treat. 2010;42(1):1-11.   Published online March 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.1.1
AbstractAbstract PDFPubReaderePub

A progressively rising level of serum prostate specific antigen (PSA) after radical prostatectomy (RP) invariably indicates the recurrence of prostate cancer. The optimal management of patients with post-RP PSA relapse has remained uncertain due to a wide variability in the natural course of post-RP PSA relapse and the inability to separate a recurrent disease confined to the prostate bed from that with occult distant metastasis. Management uncertainty is further compounded by the lack of phase III clinical studies demonstrating which therapeutic approach, if any, would prolong life with no significant morbidity. Radiotherapy has been the main therapeutic modality with a curative potential for patients with post-RP PSA relapse. This review article depicts issues and challenges in the management of patients with post-RP PSA relapse, presents the literature data for the efficacy of salvage radiotherapy, either alone or in combination of androgen ablation therapy, and discusses future directions that can optimize treatment strategies.

Citations

Citations to this article as recorded by  
  • Diospyros rhodocalyx Kurz induces mitochondrial-mediated apoptosis via BAX, Bcl-2, and caspase-3 pathways in LNCaP human prostate cancer cell line
    Chayisara Phongsuwichetsak, Thummaruk Suksrichavalit, Chawalit Chatupheeraphat, Warawan Eiamphungporn, Sakda Yainoy, Vichanan Yamkamon
    PeerJ.2024; 12: e17637.     CrossRef
  • Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial
    Elton Trigo Teixeira Leite, Clarissa Cerchi Angotti Ramos, Victor Augusto Bertotti Ribeiro, Bernardo Peres Salvajoli, William Carlos Nahas, João Victor Salvajoli, Fabio Ynoe Moraes
    International Journal of Radiation Oncology*Biology*Physics.2021; 109(5): 1263.     CrossRef
  • Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
    Olayinka A. Abiodun-Ojo, Ashesh B. Jani, Akinyemi A. Akintayo, Oladunni O. Akin-Akintayo, Oluwaseun A. Odewole, Funmilayo I. Tade, Shreyas S. Joshi, Viraj A. Master, Bridget Fielder, Raghuveer K. Halkar, Chao Zhang, Subir Goyal, Mark M. Goodman, David M.
    Journal of Nuclear Medicine.2021; 62(8): 1089.     CrossRef
  • Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis
    Changhoon Song, Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Seok-Soo Byun, Choung-Soo Kim, Sang Eun Lee, Jae-Sung Kim, Christopher J.D. Wallis
    PLOS ONE.2019; 14(4): e0215057.     CrossRef
  • Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
    Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, Jean-Léon Lagrange, Stéphane Supiot, Yazid Belkacemi, Didier Peiffert, Nedla Allouache, Bernard M Dubray, Stéphanie Servagi-Vernat, Jean-Philippe Suchaud, Gilles Crehan
    The Lancet Oncology.2019; 20(12): 1740.     CrossRef
  • Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy
    Esther Mena, Maria L. Lindenberg, Joanna H. Shih, Stephen Adler, Stephanie Harmon, Ethan Bergvall, Deborah Citrin, William Dahut, Anita T. Ton, Yolanda McKinney, Juanita Weaver, Philip Eclarinal, Alicia Forest, George Afari, Sibaprasad Bhattacharyya, Ronn
    European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(1): 4.     CrossRef
  • Recent advances in radiation oncology: multimodal targeting of high risk and recurrent prostate cancer
    Young Kwok, Adeel Kaiser, Stephanie R. Rice, Randi Cohen, Mark Mishra
    Current Opinion in Oncology.2018; 30(3): 165.     CrossRef
  • Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer
    Oladunni O. Akin-Akintayo, Ashesh B. Jani, Oluwaseun Odewole, Funmilayo I. Tade, Peter T. Nieh, Viraj A. Master, Leah M. Bellamy, Raghuveer K. Halkar, Chao Zhang, Zhengjia Chen, Mark M. Goodman, David M. Schuster
    Clinical Nuclear Medicine.2017; 42(1): e22.     CrossRef
  • The Trend of Uro-Oncologist About Blood Test and Imaging Studies for the Diagnosis of Biochemical Recurrence in Korea
    Sung Pil Seo, Won Tae Kim, Ho Won Kang, Yong-June Kim, Sang-Cheol Lee, Wun-Jae Kim, So Young Kim, Jong-Hyock Park, Seok Joong Yun
    The Korean Journal of Urological Oncology.2017; 15(3): 131.     CrossRef
  • Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy
    Wan Song, Hwang Gyun Jeon, Hyun Hwan Sung, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee
    International Journal of Urology.2016; 23(1): 56.     CrossRef
  • Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
    Christian Carrie, Ali Hasbini, Guy de Laroche, Pierre Richaud, Stéphane Guerif, Igor Latorzeff, Stéphane Supiot, Mathieu Bosset, Jean-Léon Lagrange, Véronique Beckendorf, François Lesaunier, Bernard Dubray, Jean-Philippe Wagner, Tan Dat N'Guyen, Jean-Phil
    The Lancet Oncology.2016; 17(6): 747.     CrossRef
  • Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial
    Eduard Schreibmann, David M. Schuster, Peter J. Rossi, Joseph Shelton, Sherrie Cooper, Ashesh B. Jani
    International Journal of Radiation Oncology*Biology*Physics.2016; 96(1): 206.     CrossRef
  • Detection of a second malignancy in prostate cancer patients by using [18F]Choline PET/CT: a case series
    Martina Sollini, Francesco Pasqualetti, Marzio Perri, Gabriele Coraggio, Paolo Castellucci, Massimo Roncali, Roberto Boni, Elena Lazzeri, Maria Galeandro, Fabiola Paiar, Annibale Versari, Paola Anna Erba
    Cancer Imaging.2016;[Epub]     CrossRef
  • Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
    Xiaofang Wang, Wenjuan Zhang, Zi Yan, Yupei Liang, Lihui Li, Xiaoli Yu, Yan Feng, Shen Fu, Yanmei Zhang, Hu Zhao, Jinha Yu, Lak Shin Jeong, Xiaomao Guo, Lijun Jia
    Oncotarget.2016; 7(25): 38380.     CrossRef
  • Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study
    Takashi Mizowaki, Manabu Aoki, Katsumasa Nakamura, Atsunori Yorozu, Masaki Kokubo, Katsuyuki Karasawa, Takuyo Kozuka, Nobuaki Nakajima, Keisuke Sasai, Tetsuo Akimoto
    Journal of Radiation Research.2015; 56(4): 750.     CrossRef
  • Utilization of PSA measurement at three months following salvage radiation therapy to predict future biochemical outcome
    Michael G. Heckman, Katherine S. Tzou, Colleen S. Thomas, Thomas M. Pisansky, Steven E. Schild, William W. Wong, Richard J. Lee, Melanie C. Bois, Waleed Brinjikji, Jennifer L. Peterson, Larry C. Daugherty, Stephen J. Ko, Steven J. Buskirk
    Journal of Radiation Oncology.2014; 3(1): 81.     CrossRef
  • Anti-3-[ 18 F]FACBC Positron Emission Tomography-Computerized Tomography and 111 In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prosta
    David M. Schuster, Peter T. Nieh, Ashesh B. Jani, Rianot Amzat, F. DuBois Bowman, Raghuveer K. Halkar, Viraj A. Master, Jonathon A. Nye, Oluwaseun A. Odewole, Adeboye O. Osunkoya, Bital Savir-Baruch, Pooneh Alaei-Taleghani, Mark M. Goodman
    Journal of Urology.2014; 191(5): 1446.     CrossRef
  • Salvage Low-Dose-Rate Brachytherapy for Prostate Cancer Local Recurrence after Radical Prostatectomy: Our First three Patients
    Emilio Gastaldi, Fabrizio Gallo, Luciano Chiono, Claudio Giberti
    Urologia Journal.2014; 81(1): 46.     CrossRef
  • Lack of association between COX-2 staining level and biochemical recurrence following salvage radiation therapy for recurrent prostate cancer
    Michael G. Heckman, Katherine S. Tzou, Alexander S. Parker, Thomas M. Pisansky, Steven E. Schild, Tracy W. Hilton, Vivek N. Patel, Liset Pelaez, Li Yan Khor, Jennifer L. Peterson, Larry C. Daugherty, Laura A. Vallow, Alan Pollack, Steven J. Buskirk
    Journal of Radiation Oncology.2013; 2(3): 309.     CrossRef
  • Treatment of men with rising prostate-specific antigen levels following radical prostatectomy
    Katherine Tzou, Winston W Tan, Steven Buskirk
    Expert Review of Anticancer Therapy.2011; 11(1): 125.     CrossRef
  • Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT
    David M. Schuster, Bital Savir-Baruch, Peter T. Nieh, Viraj A. Master, Raghuveer K. Halkar, Peter J. Rossi, Melinda M. Lewis, Jonathon A. Nye, Weiping Yu, F. DuBois Bowman, Mark M. Goodman
    Radiology.2011; 259(3): 852.     CrossRef
  • EUS-guided fiducial placement after radical prostatectomy before targeted radiation therapy for prostate cancer recurrence
    Julie Yang, May Abdel-Wahab, Afonso Ribeiro
    Gastrointestinal Endoscopy.2011; 73(6): 1302.     CrossRef
  • 13,094 View
  • 86 Download
  • 22 Crossref
Close layer
Original Article
Biopsy Related Prostate Status Does Not Affect on the Clinicopathological Outcome of Robotic Assisted Laparoscopic Radical Prostatectomy
Hoon Choi, Young Hwii Ko, Sung Gu Kang, Seok Ho Kang, Hong Seok Park, Jun Cheon, Vipul R. Patel
Cancer Res Treat. 2009;41(4):205-210.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.205
AbstractAbstract PDFPubReaderePub
Purpose

To determine whether the biopsy core number and time interval between prostate biopsy and radical prostatectomy affect the operative and oncologic outcome of robot assisted laparoscopic radical prostatectomy (RALP).

Materials and Methods

From January 2008 to April 2009, a single surgeon performed 72 RALPs after an initial learning period of 30 cases. The relationship between time from biopsy to prostatectomy and biopsy core number with operative time and estimated blood loss (EBL) were initially evaluated with a linear regression model. These patients were classified into groups according to whether the interval from biopsy to RALP was within four weeks or not, and whether there were less than or greater than 10 core specimens removed.

Results

RALP was performed in 34 patients within four weeks of biopsy, and in 38 patients more than 4 weeks after biopsy. According to the number of core specimens removed, less than 10 cores were performed in 10 patients, and more than 10 cores were performed in 62 patients. Using an interval of 4 weeks as the cutoff point, early surgery was associated with longer operating time (232.6 vs 208.8 min) and increased estimated blood loss (305.1 vs 276.9 mL). For cases with more than 10 biopsy cores, there was a slight increase in operative time (229.2 vs 210.3 min). None of these differences were statistically significant by multivariate analysis.

Conclusion

Our data suggests that there is no reason to delay RALP to more than 4 weeks after prostate biopsy. It also revealed that the number of biopsy cores (up to 14) did not influence operative outcome. Thus, RALP is a feasible procedure regardless of the biopsy related prostate state.

Citations

Citations to this article as recorded by  
  • Effect of Transperineal Versus Transrectal Prostate Biopsy on the Quality of Hydrogel Spacer Placement in Men Prior to Radiation Therapy for Prostate Cancer
    Michael E. Rezaee, Ulysses Gardner, Mark N. Alshak, Stephen C. Greco, Daniel Y. Song, Michael Goldstein, Christian P. Pavlovich
    Urology.2023; 182: 27.     CrossRef
  • Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis
    Jie Li, Qing Jiang, Qiubo Li, Yuanfeng Zhang, Liang Gao
    International Urology and Nephrology.2020; 52(4): 619.     CrossRef
  • Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes
    Minke He, Yaohui Li, Zhuoyi Xiang, Li-an Sun, Yanjun Zhu, Xiaoyi Hu, Jianming Guo, Hang Wang
    Medicine.2018; 97(36): e11686.     CrossRef
  • A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy
    Akash Bijlani, April E. Hebert, Mike Davitian, Holly May, Mark Speers, Robert Leung, Nihal E. Mohamed, Henry S. Sacks, Ashutosh Tewari
    Value in Health.2016; 19(4): 391.     CrossRef
  • Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach
    Bumsoo Park, Seol Ho Choo, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi
    Journal of Korean Medical Science.2014; 29(12): 1688.     CrossRef
  • Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
    In Sung Kim, Woong Na, Jung Su Nam, Jong Jin Oh, Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Sang Eun Lee
    Korean Journal of Urology.2011; 52(10): 664.     CrossRef
  • Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml
    Jin-Seok Chang, Hoon Choi, Young-Seop Chang, Jin-Bum Kim, Mi Mi Oh, Du Geon Moon, Jae Hyun Bae, Jun Cheon
    Korean Journal of Urology.2011; 52(12): 809.     CrossRef
  • 9,518 View
  • 51 Download
  • 7 Crossref
Close layer
Case Report
Cancer of Unknown Primary Finally Revealed to Be a Metastatic Prostate Cancer: A Case Report
Jung Yeon Cho, Eun Jin Shim, In Seon Kim, Eun Mi Nam, Moon Young Choi, Kyung Eun Lee, Yeung Chul Mun, Chu Myoung Seoung, Soon Nam Lee, Dong Eun Song, Woon Sup Han
Cancer Res Treat. 2009;41(1):45-49.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.45
AbstractAbstract PDFPubReaderePub

The vast majority of patients with metastatic prostate cancer present with bone metastases and high prostate specific antigen (PSA) level. Rarely, prostate cancer can develop in patients with normal PSA level. Here, we report a patient who presented with a periureteral tumor of unknown primary site that was confirmed as prostate adenocarcinoma after three years with using specific immunohistochemical examination. A 64-year old man was admitted to our hospital with left flank pain associated with masses on the left pelvic cavity with left hydronephrosis. All tumor markers including CEA, CA19-9, and PSA were within the normal range. After an exploratory mass excision and left nephrectomy, the pelvic mass was diagnosed as poorly differentiated carcinoma without specific positive immunohistochemical markers. At that time, we treated him as having a cancer of unknown primary site. After approximately three years later, he revisited the hospital with a complaint of right shoulder pain. A right scapular mass was newly detected with a high serum PSA level (101.7 ng/ml). Tissues from the scapular mass and prostate revealed prostate cancer with positive immunoreactivity for P504S, a new prostate cancer-specific gene. The histological findings were the same as the previous pelvic mass; however, positive staining for PSA was observed only in the prostate mass. This case demonstrates a patient with prostate cancer and negative serological test and tissue staining that turned out to be positive during progression. We suggest the usefulness of newly developed immunohistochemical markers such as P504S to determine the specific primary site of metastatic poorly differentiated adenocarcinoma in men.

Citations

Citations to this article as recorded by  
  • A Unique Case of Prostate Carcinoma Presenting as Retroperitoneal Lymphadenopathy With Normal Levels of Prostate-Specific Antigen and a Prostate of Normal Size: A Case Report
    Swapnil Patil, Mayank Mundada, Pradnya M Diggikar, Raju Hansini Reddy, Sree Vidya Yekkaluru
    Cureus.2024;[Epub]     CrossRef
  • Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review
    Xinbing Sui, Yan Hu, Cheng Zhang, Hongming Pan, Da Li
    Oncology Letters.2016; 12(2): 1074.     CrossRef
  • Metastasis of prostate carcinoma in the mandible manifesting as numb chin syndrome
    Secil Aksoy, Kaan Orhan, Sebnem Kursun, Mehmet Eray Kolsuz, Berkan Celikten
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • 9,672 View
  • 56 Download
  • 3 Crossref
Close layer
Original Articles
Influence of Estrogen and Polyamines on Mifepristone-induced Apoptosis in Prostate Cancer Cells
Eun Kyung Choi, Hwi-June Song, Min S. Park, Byeong Gee Kim
Cancer Res Treat. 2004;36(1):85-90.   Published online February 29, 2004
DOI: https://doi.org/10.4143/crt.2004.36.1.85
AbstractAbstract PDFPubReaderePub
Purpose

Although androgens are the main steroids controlling the growth of prostate glands, estrogens are also important in the regulation of its growth. Prostate cancer cells, like other cancer cells, maintain high levels of polyamines. In LNCaP cells, apoptosis is induced by mifepristone. During the process of cell death, the regulation of ROS production, caspase-3 activation and poly (ADP-ribose) polymerase cleavage were investigated in the presence of estrogen and polyamines to identify their possible roles.

Materials and Methods

The cell growth was assessed using the MTT assay, and theintracellular ROS production by the DCFH-DA assay. The p53 protein expression, activation of caspase-3 and PARP cleavage were checked by Western blotting, with specific antibodies to each.

Results

The growth and viability of the cells were significantly inhibited, in a dose- and time-dependent manners, by mifepristone (MIF) treatment. The production of ROSwere dependent on the MIF dosage. The activation of caspase-3 and cleavage of PARPalso increased with the duration of MIF treatment. The expression of p53 protein also increased with increases in the MIF incubation time. E2 severely inhibited the ROS production, caspase-3 activation and PARP cleavage. However, polyamines only inhibited the ROS production, without influencing the caspase-3 activation or PARP cleavage.

Conclusion

In LNCaP cells, MIF induces apoptosis through ROS production. The expression of p53 protein, caspase-3 activation and PARP cleavage accompanied the process of apoptosis. The apoptotic processes were inhibited by E2, but polyamines only inhibited the ROS production, implying the multifunctional role of E2, in addition to its role as a free radical scavenger.

Citations

Citations to this article as recorded by  
  • Dexamethasone along with ciprofloxacin modulates S. aureus induced microglial inflammation via glucocorticoid (GC)-GC receptor-mediated pathway
    Rajen Dey, Biswadev Bishayi
    Microbial Pathogenesis.2020; 145: 104227.     CrossRef
  • Synergistic Effect of Ionizing Radiation and β-lapachone against RKO Human Colon Adenocarcinoma Cells
    Eun Jung Kim, In-Mi Ji, Ki-Jung Ahn, Eun Kyung Choi, Heon-Jin Park, Byung Uk Lim, Chang W. Song, Heon Joo Park
    Cancer Research and Treatment.2005; 37(3): 183.     CrossRef
  • 9,264 View
  • 60 Download
  • 2 Crossref
Close layer
Permanent Genotypic and Phenotypic Change of Prostate Cancer Cell Line LNCaP through Cellular Interactions with Prostate or Bone Fibroblasts in vitro or in vivo
Hong Woo Rhee, Sung Hak Kang, Tae Kon Hwang, Leland W K Chung
J Korean Cancer Assoc. 2001;33(2):168-177.
AbstractAbstract PDF
PURPOSE
Cell-cell interactions determine normal prostate development and subsequent neoplastic transfor mation. The progression of prostate cancer from androgen-dependent to androgen-independent states involves multiple steps of genetic changes mediated by tumor-microenvironment interactions. To understand the epigenetic factors that lead to progression, we studied if 1) androgen-dependent and non-metastatic LNCaP may interact with prostate or bone fibroblasts under microgravity-simulated conditions in vitro. 2) LNCaP may interact with prostate fibroblasts in vivo, and acquire androgen-independence and metastatic potential.
MATERIALS AND METHODS
The LNCaP sublines were generated as follows. 1) LNCaP cells were grown in vitro either alone or with prostate or bone fibroblasts under microgravity-simulated conditions. 2) LNCaP cells were grown in vivo as chimeric tumors with prostate fibroblasts. The LNCaP sublines were characterized by studies of chromosomal analysis, comparative genomic hybridization and, in vivo tumorigenicity and metastatic potential.
RESULTS
In comparison to the parental LNCaP cells, the LNCaP sublines underwent permanent genotypic and phenotypic changes manifested in androgen-independence and metastatic potential.
CONCLUSION
These results emphasize the importance of cell-cell interaction as a critical determinant that could "induce" or "select" progenies favoring enhanced prostate cancer growth and progression. This concept favors the development of toxic gene therapy targeting both prostate cancer epithelium and supporting bone stroma for an effective eradication and prevention of prostate cancer bone metastasis.
  • 2,531 View
  • 21 Download
Close layer
Immunohistochemical Expression of p53 and Cathepsin D in Prostatic Carcinoma
Dae Joong Kim, Eui Han Kim, Seung Ha Yang, Chang Jin Kim
J Korean Cancer Assoc. 2000;32(4):810-816.
AbstractAbstract PDF
PURPOSE
To evaluate the prognostic significances of p53 and cathepsin D in the prostatic carcinoma, we compared them to other prognostic factors, such as nuclear grade and clinical stage.
MATERIALS AND METHODS
The material consisted of 40 paraffin-embedded, primary prostate carcinomas. We examined the expression of p53 and cathepsin D using immunohistochemical staining and compared their expression with the grade and stage.
RESULTS
The expressions of p53 were noted in the nucleus of tumor cells and cathepsin D were noted in the cytoplasm of tumor cells. Thirteen of 40 tumors were positive for p53. There were more expressing p53 in samples (40%) from prostatic cancer with a high Gleason score group than in samples (28%) from prostatic cancer with low Gleason score group. The expression of p53 was 22% in clinical stage B and C groups and 35% in clinical stage D group. These results showed that p53 expression was not statistically correlated with Gleason score and clinical stage, but there were trends to increased p53 expression with high Gleason score and progressed clinical stage (p>0.05). Progressed clinical stage group showed higher expression of cathepsin D than early clinical stage group. However, there were no statistical correlations between expression of cathepsin D and Gleason score, and clinical stage (p>0.05).
CONCLUSION
These results suggest that the overexpression of p53 and cathepsin D may be associated with tumor differentiation and clinical stage, but have limited prognostic value in prostatic carcinoma.
  • 2,485 View
  • 21 Download
Close layer
Matrix Metalloproteinase Expression and Ldegrees Calization in Human Prostate Adendegrees Carcinoma: An Immunohistdegrees Chemical Study of MMP-2, -9, -3, -7
Jung Weon Shim, Young Goo Lee, Tae Jin Lee, Jae Y Ro
J Korean Cancer Assoc. 2000;32(3):629-637.
AbstractAbstract PDF
No abstract available.
  • 2,383 View
  • 17 Download
Close layer
Change of Bone Mineral Density after 1,25(OH)2VitD Therapy In Newly Diagnosed Prostate Cancer Patients Treated with Total Androgen Blockade: The Prospective Study
P B Jung, D G Moon, D S Lee, J J Kim, S K Koh, J Cheon
J Korean Cancer Assoc. 2000;32(2):360-366.
AbstractAbstract PDF
No abstract available.
  • 2,086 View
  • 14 Download
Close layer
Study on the Expression of Prostate Specific Antigen ( PSA ) and Effects of Androgen on Induction of Apoptosis in Human Prostate Cell Lines
M S Lee, E J Kwon
J Korean Cancer Assoc. 2000;32(2):350-359.
AbstractAbstract PDF
PURPOSE
Prostate specific antigen (PSA) is expressed exclusively in human prostatic epithelial cells. PSA protein has been an important biological marker for prostate cancer. Until now, very little was known about the regulation of PSA expression in prostatic cells. In this study, we were used human prostate cell lines (pRNS-1-1 and LNCaP) as in vitro model system to investigate the induction of apoptosis and the changes of expression of prostate specific antigen (PSA) in response to androgen (5 a-dihydrotestosterone: DHT) and/or 12-tetradecanoyl phorbol 13-acetate (TPA).
MATERIALS AND METHODS
DNA gel electrophoresis, flow cytometry, and microscopic analysis for the induction of apoptosis, and western blot analysis for PSA expression were used to characterize DHT and/or TPA response in human prostate cells.
RESULTS
TPA induced LNCaP Cell death. Cells exhibited morphological and ultrastructural features indication of apoptosis, cytoplasmic contraction, condensation of nuclear chromatin, and formation of membrane-bound apoptotic bodies were observed. The characteristic endonuclease- generated DNA ladder, commonly associated with apoptosis, were observed in TPA-treated and accumulation of cells in Ao (apoptotic region) LNCaP cells. But pRNS-1-1 cells showed no DNA fragmentation, no apoptotic bodies, and accumulation of cells in Ao was not observed. TPA resulted in dose-dependent inhibition of PSA expression. In contrast, DHT induced increase in PSA expression and decrease on degradation of DNA into oligonucleosomal size DNA fragment.
CONCLUSION
The data presented here suggest that DHT protects against TPA-induced apoptosis in cycling LNCaP cells and PSA expression is up-regulated predominantly by androgen, down-regulated in a dose dependent fashion by TPA.
  • 2,695 View
  • 30 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP